[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 15157
1. Vonk MM, Diks MAP, Wagenaar L, Smit JJ, Pieters RHH, Garssen J, van Esch BCAM, Knippels LMJ: Improved Efficacy of Oral Immunotherapy Using Non-Digestible Oligosaccharides in a Murine Cow's Milk Allergy Model: A Potential Role for Foxp3+ Regulatory T Cells. Front Immunol; 2017;8:1230
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, there are some concerns regarding its safety and long-term efficacy.
  • Concisely, FOS supplementation significantly improved OIT in the acute allergic skin response, %Foxp3+ Tregs and %LAP+ Th3 cells in MLN, and serum galectin-9 levels.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nutr. 2010 Apr;140(4):835-41 [20164372.001]
  • [Cites] J Allergy Clin Immunol. 2016 Apr;137(4):984-997 [27059726.001]
  • [Cites] Nat Med. 2014 Feb;20(2):159-66 [24390308.001]
  • [Cites] J Immunol. 2009 Nov 15;183(10):6395-402 [19841174.001]
  • [Cites] J Allergy Clin Immunol. 2015 Mar;135(3):737-44.e8 [25592987.001]
  • [Cites] J Allergy Clin Immunol. 1999 Feb;103(2 Pt 1):206-14 [9949309.001]
  • [Cites] Int Arch Allergy Immunol. 2008;147(2):125-34 [18520157.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2016 Jun 1;310(11):G1138-46 [27151945.001]
  • [Cites] Nature. 2013 Dec 19;504(7480):451-5 [24226773.001]
  • [Cites] Pediatr Allergy Immunol. 2014 Dec;25(8):747-54 [25410019.001]
  • [Cites] J Allergy Clin Immunol. 2005 Nov;116(5):961-8; quiz 969 [16275361.001]
  • [Cites] J Innate Immun. 2013;5(6):625-38 [23735749.001]
  • [Cites] Eur J Pharmacol. 2011 Sep;668 Suppl 1:S117-23 [21810418.001]
  • [Cites] Adv Immunol. 2014;121:91-119 [24388214.001]
  • [Cites] Acta Paediatr Suppl. 2005 Oct;94(449):18-21 [16214760.001]
  • [Cites] J Leukoc Biol. 2011 May;89(5):685-95 [21233408.001]
  • [Cites] J Gastroenterol Hepatol. 2017 Mar;32 Suppl 1:64-68 [28244671.001]
  • [Cites] Nat Commun. 2015 Apr 01;6:6734 [25828455.001]
  • [Cites] Am J Clin Nutr. 2013 Aug;98(2):572S-7S [23824724.001]
  • [Cites] Allergy. 2017 Aug;72 (8):1133-1147 [28058751.001]
  • [Cites] Proc Nutr Soc. 2003 Feb;62(1):67-72 [12740060.001]
  • [Cites] World Allergy Organ J. 2015 May 14;8(1):17 [26023323.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3097-104 [16014565.001]
  • [Cites] Cell Mol Immunol. 2017 Sep;14 (9):770-782 [27063469.001]
  • [Cites] Brain Behav Immun. 2014 Mar;37:197-206 [24333160.001]
  • [Cites] Intern Med J. 2017 Mar;47(3):256-261 [28260260.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1757-64 [17620361.001]
  • [Cites] Allergy. 2012 Mar;67(3):343-52 [22229637.001]
  • [Cites] Pediatr Allergy Immunol. 2016 Mar;27(2):117-25 [26593873.001]
  • [Cites] Pediatr Allergy Immunol. 2015 May;26(3):291-294 [25692393.001]
  • [Cites] Allergy. 2015 Sep;70(9):1091-102 [25966668.001]
  • [Cites] Carbohydr Polym. 2013 Mar 1;93(1):263-5 [23465928.001]
  • [Cites] Curr Allergy Asthma Rep. 2015 Jun;15(6):35 [26141581.001]
  • [Cites] Clin Exp Allergy. 2013 Jan;43(1):92-102 [23278884.001]
  • [Cites] Nutr Clin Pract. 2012 Apr;27(2):201-14 [22367888.001]
  • [Cites] Pediatr Allergy Immunol. 2010 Dec;21(8):1179-88 [20444147.001]
  • [Cites] Immunity. 2008 Nov 14;29(5):771-81 [18993084.001]
  • [Cites] Cell Rep. 2016 Jun 21;15(12 ):2809-24 [27332875.001]
  • [Cites] Allergy. 2016 Nov;71(11):1552-1560 [27015954.001]
  • [Cites] J Clin Gastroenterol. 2006 Mar;40(3):235-43 [16633129.001]
  • [Cites] Eur J Pharmacol. 2011 Sep;668 Suppl 1:S124-32 [21816141.001]
  • [Cites] Clin Exp Allergy. 2013 Jul;43(7):798-810 [23786286.001]
  • [Cites] Immun Inflamm Dis. 2016 Mar 24;4(2):155-165 [27933160.001]
  • [Cites] Nat Rev Immunol. 2008 Jun;8(6):435-46 [18500229.001]
  • [Cites] PLoS One. 2015 Jul 06;10(7):e0132304 [26148091.001]
  • (PMID = 29033945.001).
  • [ISSN] 1664-3224
  • [Journal-full-title] Frontiers in immunology
  • [ISO-abbreviation] Front Immunol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; butyric acid / cow’s milk allergy / desensitization / galectin-9 / non-digestible oligosaccharides / oral immunotherapy / regulatory T cell
  •  go-up   go-down


2. Skowron K, Jakubicz A, Budzyńska A, Kaczmarek A, Grudlewska K, Reśliński A, Gospodarek-Komkowska E: Microbiological purity assessment of cosmetics used by one and several persons and cosmetics after their expiry date. Rocz Panstw Zakl Hig; 2017;68(2):191-197
MedlinePlus Health Information. consumer health - Cosmetics.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microbiological purity assessment of cosmetics used by one and several persons and cosmetics after their expiry date
  • Background: Microbiological purity of cosmetics provides safety of users during their use, prevents physicochemical changes of a preparation, infections and diseases of the skin.
  • Objective: The aim of this study was to assess the level of microbiological contamination of cosmetics used by one person and by several people and cosmetics after their expiry date in relations to standards for marketed cosmetics, ensuring safety of their use.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28646837.001).
  • [ISSN] 0035-7715
  • [Journal-full-title] Roczniki Panstwowego Zakladu Higieny
  • [ISO-abbreviation] Rocz Panstw Zakl Hig
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Cosmetics; 0 / Toothpastes
  •  go-up   go-down


3. Sowada J, Lemoine L, Schön K, Hutzler C, Luch A, Tralau T: Toxification of polycyclic aromatic hydrocarbons by commensal bacteria from human skin. Arch Toxicol; 2017 Jun;91(6):2331-2341

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxification of polycyclic aromatic hydrocarbons by commensal bacteria from human skin.
  • This study now shows that readily isolable skin commensals transform B[a]P into a range of highly cyto- and genotoxic metabolites that are excreted in toxicologically relevant concentrations during growth.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2005 Jul 11;33(12):3799-811 [16009812.001]
  • [Cites] J Hazard Mater. 2009 Sep 30;169(1-3):492-7 [19414215.001]
  • [Cites] Arch Toxicol. 2016 Jun;90(6):1449-58 [26238291.001]
  • [Cites] Nat Rev Cancer. 2005 Feb;5(2):113-25 [15660110.001]
  • [Cites] Atmos Environ. 1969 Sep;3(5):565-72 [4187590.001]
  • [Cites] Science. 2009 Dec 18;326(5960):1694-7 [19892944.001]
  • [Cites] Appl Microbiol Biotechnol. 2006 Jul;71(4):522-32 [16317545.001]
  • [Cites] Environ Mol Mutagen. 2005 Mar-Apr;45(2-3):106-14 [15688365.001]
  • [Cites] EXS. 2009;99:151-79 [19157061.001]
  • [Cites] MBio. 2013 Oct 29;4(6):e00782-13 [24169577.001]
  • [Cites] Arch Toxicol. 2014 Dec;88(12):2135-90 [25370008.001]
  • [Cites] Environ Toxicol Chem. 2001 Mar;20(3):632-43 [11349866.001]
  • [Cites] FEMS Microbiol Lett. 2003 Jun 27;223(2):177-83 [12829283.001]
  • [Cites] Methods Enzymol. 1990;188:148-53 [2280701.001]
  • [Cites] J Hazard Mater. 2009 Sep 30;169(1-3):1-15 [19442441.001]
  • [Cites] Chem Res Toxicol. 2011 Oct 17;24(10 ):1653-67 [21916506.001]
  • [Cites] Environ Sci Pollut Res Int. 2015 Nov;22(21):16393-404 [25471715.001]
  • [Cites] FEMS Microbiol Ecol. 2014 Apr;88(1):129-39 [24372170.001]
  • [Cites] Crit Rev Microbiol. 2015;41(3):326-40 [24645635.001]
  • [Cites] Cell Mol Life Sci. 2015 Apr;72(8):1499-515 [25548803.001]
  • [Cites] Cell. 2016 May 5;165(4):801-11 [27153494.001]
  • [Cites] Science. 2009 May 29;324(5931):1190-2 [19478181.001]
  • [Cites] J Environ Monit. 2007 Sep;9(9):1001-8 [17726562.001]
  • [Cites] Toxicol Lett. 2013 Apr 12;218(2):97-104 [23391484.001]
  • [Cites] EXS. 2009;99:57-86 [19157058.001]
  • [Cites] Carcinogenesis. 1998 Oct;19(10):1847-53 [9806168.001]
  • [Cites] Environ Monit Assess. 2008 Apr;139(1-3):107-18 [17566864.001]
  • [Cites] Biomed Chromatogr. 2016 Mar;30(3):474-83 [26230188.001]
  • [Cites] PLoS One. 2016 Jan 15;11(1):e0147239 [26771904.001]
  • [Cites] Cell. 2012 Mar 16;148(6):1258-70 [22424233.001]
  • [Cites] Drug Metab Pharmacokinet. 2006 Aug;21(4):257-76 [16946553.001]
  • [Cites] Expert Opin Drug Metab Toxicol. 2015 Mar;11(3):411-25 [25476418.001]
  • [Cites] Chem Res Toxicol. 1995 Jan-Feb;8(1):136-42 [7703357.001]
  • [Cites] FEMS Microbiol Rev. 2008 Nov;32(6):927-55 [18662317.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):908-15 [10706104.001]
  • [Cites] Mucosal Immunol. 2012 Sep;5(5):567-79 [22617837.001]
  • [Cites] Exp Dermatol. 2012 May;21(5):364-9 [22509834.001]
  • [Cites] Curr Opin Chem Biol. 2013 Jun;17(3):379-84 [23680493.001]
  • [Cites] Environ Mol Mutagen. 2016 Apr;57(3):229-35 [26919089.001]
  • [Cites] Biochemistry. 1977 Apr 5;16(7):1467-73 [191070.001]
  • [Cites] Toxicol Sci. 2013 Feb;131(2):351-9 [23148024.001]
  • (PMID = 28378121.001).
  • [ISSN] 1432-0738
  • [Journal-full-title] Archives of toxicology
  • [ISO-abbreviation] Arch. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; Benzo[a]pyrene / Cytotoxicity / Genotoxicity / Microbiome / PAHs / Polycyclic aromatic hydrocarbons / Toxification
  •  go-up   go-down


Advertisement
4. Woodley DT, Cogan J, Hou Y, Lyu C, Marinkovich MP, Keene D, Chen M: Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients. J Clin Invest; 2017 Aug 01;127(8):3028-3038
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A double-blind, placebo-controlled pilot trial assessed safety and efficacy of topical and intradermal gentamicin in 5 RDEB patients with nonsense mutations.
  • The intradermal arm tested daily intradermal injection of gentamicin solution (8 mg) or placebo into 2 intact skin sites for 2 days in 4 of 5 patients.
  • Primary outcomes were induction of type VII collagen and AFs at the test sites and safety assessment.
  • Newly created type VII collagen varied from 20% to 165% of that expressed in normal human skin and persisted for 3 months.
  • Type VII collagen induction did not generate anti-type VII collagen autoantibodies in patients' blood or skin.
  • [MeSH-minor] Administration, Topical. Adult. Alleles. Autoantibodies / chemistry. Child. Codon, Nonsense. Double-Blind Method. Female. Genes, Recessive. Humans. Injections, Intradermal. Keratinocytes / cytology. Male. Patient Safety. Pilot Projects. Skin / drug effects. Treatment Outcome. Wound Healing

  • Genetic Alliance. consumer health - Dystrophic Epidermolysis Bullosa.
  • Genetic Alliance. consumer health - Epidermolysis Bullosa.
  • Genetic Alliance. consumer health - Recessive dystrophic epidermolysis bullosa.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Ther. 2009 Sep;17(9):1605-15 [19568221.001]
  • [Cites] BMC Med. 2007 Mar 29;5:5 [17394637.001]
  • [Cites] J Invest Dermatol. 2003 Nov;121(5):1021-8 [14708601.001]
  • [Cites] J Clin Invest. 1993 Oct;92(4):1831-9 [7691888.001]
  • [Cites] Br J Dermatol. 2015 Sep;173(3):821-3 [25703736.001]
  • [Cites] J Invest Dermatol. 2008 Sep;128(9):2179-89 [18385758.001]
  • [Cites] N Engl J Med. 2010 Aug 12;363(7):629-39 [20818854.001]
  • [Cites] Arch Dermatol Res. 1994;287(1):16-22 [7726631.001]
  • [Cites] Mol Ther. 2014 Oct;22(10):1741-52 [25155989.001]
  • [Cites] Nat Med. 2004 Jul;10(7):693-5 [15195089.001]
  • [Cites] Nat Genet. 2002 Dec;32(4):670-5 [12426566.001]
  • [Cites] J Am Acad Dermatol. 2013 Dec;69(6):898-908.e7 [24075228.001]
  • [Cites] Nat Med. 2002 Oct;8(10):1166-70 [12244305.001]
  • [Cites] N Engl J Med. 1970 Aug 27;283(9):451-6 [4393577.001]
  • [Cites] J Clin Invest. 2007 Mar;117(3):683-92 [17290305.001]
  • [Cites] Am J Respir Crit Care Med. 2000 Mar;161(3 Pt 1):860-5 [10712334.001]
  • [Cites] Clin Pharmacol Ther. 2007 Jan;81(1):99-103 [17186006.001]
  • [Cites] Mol Ther. 2004 Aug;10(2):318-26 [15294178.001]
  • [Cites] Cell Discov. 2015;1:null [26491543.001]
  • [Cites] J Invest Dermatol. 1995 Feb;104(2):231-5 [7530271.001]
  • [Cites] J Invest Dermatol. 2013 Jul;133(7):1910-3 [23321924.001]
  • [Cites] Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19483-8 [24218596.001]
  • [Cites] Ann Neurol. 2010 Jun;67(6):771-80 [20517938.001]
  • [Cites] J Invest Dermatol. 1993 Sep;101(3):252-5 [8370960.001]
  • [Cites] J Am Acad Dermatol. 2009 Feb;60(2):203-11 [19026465.001]
  • [Cites] Ann Neurol. 2001 Jun;49(6):706-11 [11409421.001]
  • [Cites] J Invest Dermatol. 2014 Apr;134(4):1138-40 [24213372.001]
  • [Cites] Mol Ther. 2007 Mar;15(3):628-35 [17245357.001]
  • [Cites] Hum Mutat. 2011 Oct;32(10):1100-7 [21681854.001]
  • [Cites] J Clin Invest. 1999 Aug;104(4):375-81 [10449429.001]
  • [Cites] J Invest Dermatol. 2001 Mar;116(3):483-4 [11231335.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2014;15:371-94 [24773318.001]
  • [Cites] Nat Med. 1997 Nov;3(11):1280-4 [9359706.001]
  • [Cites] J Cell Biol. 1986 Oct;103(4):1577-86 [3771648.001]
  • [Cites] J Invest Dermatol. 2015 Dec;135(12):3060-7 [26203639.001]
  • [Cites] N Engl J Med. 2003 Oct 9;349(15):1433-41 [14534336.001]
  • [Cites] Mol Ther. 2013 Jul;21(7):1335-44 [23670575.001]
  • [Cites] Mol Ther. 2009 Jan;17(1):26-33 [19018253.001]
  • [Cites] J Clin Invest. 2003 Jan;111(2):251-5 [12531881.001]
  • [Cites] N Engl J Med. 1984 Apr 19;310(16):1007-13 [6369131.001]
  • [Cites] Hum Mutat. 2012 Feb;33(2):327-31 [22058051.001]
  • [Cites] JAMA. 2016 Nov 1;316(17 ):1808-1817 [27802546.001]
  • [Cites] Exp Dermatol. 1992 Dec;1(5):221-9 [1365323.001]
  • [Cites] Trends Genet. 2008 Nov;24(11):552-63 [18937996.001]
  • [Cites] Trends Mol Med. 2012 Nov;18(11):679-88 [23083810.001]
  • [Cites] J Invest Dermatol. 1985 May;84(5):374-7 [4039741.001]
  • [Cites] J Clin Invest. 1988 Mar;81(3):683-7 [3278005.001]
  • [Cites] Science. 2005 Mar 18;307(5716):1773-6 [15774758.001]
  • (PMID = 28691931.001).
  • [ISSN] 1558-8238
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / R01 AR055914; United States / NIAMS NIH HHS / AR / RC4 AR060535
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / COL7A1 protein, human; 0 / Codon, Nonsense; 0 / Collagen Type VII; 0 / Gentamicins; 0 / Protein Synthesis Inhibitors
  •  go-up   go-down


5. Zhang W, Chen L, Chen J, Wang L, Gui X, Ran J, Xu G, Zhao H, Zeng M, Ji J, Qian L, Zhou J, Ouyang H, Zou X: Silk Fibroin Biomaterial Shows Safe and Effective Wound Healing in Animal Models and a Randomized Controlled Clinical Trial. Adv Healthc Mater; 2017 May;6(10)

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here a silk fibroin film is developed and its translational potential is investigated for skin repair by performing comprehensive preclinical and clinical studies to fully evaluate its safety and effectiveness.
  • In vivo rabbit full-thickness skin defect study shows that the silk fibroin film effectively reduces the average wound healing time with better skin regeneration compared with the commercial wound dressings.
  • Subsequent assessment in porcine model confirms its long-term safety and effectiveness for full-thickness skin defects.
  • Therefore, the study provides systematic preclinical and clinical evidence that the silk fibroin film promotes wound healing thereby establishing a foundation towards its application for skin repair and regeneration in the clinic.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
  • (PMID = 28337854.001).
  • [ISSN] 2192-2659
  • [Journal-full-title] Advanced healthcare materials
  • [ISO-abbreviation] Adv Healthc Mater
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; bench to bedside / controlled clinical trial / silk fibroin biomaterial / skin repair and regeneration / wound healing
  •  go-up   go-down


6. Lee E, Yun J, Ha J, Park BC, Park GH, Kim HR, Hong SP, Kim KB, Kim MH: Assessment of exposure for baby cosmetic care products in a Korean population. Food Chem Toxicol; 2017 Aug;106(Pt A):107-113

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of exposure for baby cosmetic care products in a Korean population.
  • Assessment of exposure to cosmetic products via the skin is important for evaluating the risks associated with the use of these products.
  • Of specific note, 3.51% of the lotion in a wet wipe was transferred to the skin.
  • [MeSH-minor] Child, Preschool. Consumer Product Safety. Female. Humans. Infant. Male. Republic of Korea. Risk Assessment. Skin / chemistry. Skin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28549762.001).
  • [ISSN] 1873-6351
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cosmetics
  • [Keywords] NOTNLM ; Baby cosmetic products / Exposure assessment / Korean population / Seasonal variation / Wet wipes lotion transfer
  •  go-up   go-down


7. Bitzer J, Römer T, Lopes da Silva Filho A: The use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms - a review. Eur J Contracept Reprod Health Care; 2017 Jun;22(3):172-182
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms - a review.
  • Hyperandrogenic skin symptoms such as hirsutism, acne, seborrhea and alopecia are associated with significant quality of life and psychological impairment.
  • OBJECTIVE: To review the data on the efficacy and safety of CPA 2 mg/EE 35 μg for the treatment of hyperandrogenic skin symptoms in women.
  • Studies show that therapeutic response in women with hirsutism requires a long-term approach and that hyperandrogenic skin symptoms in patients with PCOS are efficiently treated.
  • Safety and tolerability data are summarized by the pharmacovigilance risk assessment committee (PRAC) of the European Medicine's Agency's (EMA).
  • CONCLUSIONS: This review provides a comprehensive overview about the efficacy of CPA 2 mg/EE 35 μg in the treatment of hyperandrogenic skin symptoms, thus allowing both health care professionals and women to balance the risks and benefits of treatment based on evidence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28447864.001).
  • [ISSN] 1473-0782
  • [Journal-full-title] The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • [ISO-abbreviation] Eur J Contracept Reprod Health Care
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Hyperandrogenism / acne / alopecia / cyproterone acetate / ethinylestradiol / hirsutism / polycystic ovary syndrome / seborrhea
  •  go-up   go-down


8. Liu Y, Flynn TJ: CYP3A4 inhibition by <i>Psoralea corylifolia</i> and its major components in human recombinant enzyme, differentiated human hepatoma HuH-7 and HepaRG cells. Toxicol Rep; 2015;2:530-534

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • <i>Psoralea corylifolia</i> (<i>P. corylifolia</i>) is a medicinal plant used primarily in herbal dietary supplements to treat skin diseases, such as vitiligo and psoriasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Xenobiotica. 2009 Mar;39(3):205-17 [19280519.001]
  • [Cites] Ann Hepatol. 2009 Jul-Sep;8(3):258-66 [19841509.001]
  • [Cites] Fitoterapia. 2013 Oct;90:44-56 [23831482.001]
  • [Cites] Aliment Pharmacol Ther. 2013 Jan;37(1):3-17 [23121117.001]
  • [Cites] Expert Opin Drug Metab Toxicol. 2012 Jul;8(7):909-20 [22568886.001]
  • [Cites] Clin Toxicol (Phila). 2009 Aug;47(7):683-5 [19640237.001]
  • [Cites] Pharmacogn Rev. 2010 Jan;4(7):69-76 [22228944.001]
  • [Cites] Biochem Pharmacol. 2013 Aug 15;86(4):529-38 [23732297.001]
  • [Cites] Drug Metab Dispos. 2006 Jan;34(1):75-83 [16204462.001]
  • [Cites] Arch Pharm Res. 2010 Feb;33(2):225-30 [20195822.001]
  • [Cites] Toxicol Lett. 2012 Feb 25;209(1):67-77 [22173200.001]
  • [Cites] Drug Metab Dispos. 2009 Dec;37(12):2330-9 [19773538.001]
  • [Cites] Curr Drug Metab. 2013 Nov;14 (9):946-68 [24160292.001]
  • [Cites] Dermatol Clin. 2014 Jul;32(3):399-413, ix-x [24891061.001]
  • [Cites] Toxicol In Vitro. 2009 Jun;23(4):748-53 [19328226.001]
  • [Cites] Pharmacol Ther. 2010 Feb;125(2):230-48 [19951720.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Jul 5;821(1):67-74 [15905140.001]
  • [Cites] Drug Metab Rev. 2007;39(4):699-721 [18058330.001]
  • [Cites] Clin Toxicol (Phila). 2005;43(6):589-91 [16255343.001]
  • (PMID = 28962388.001).
  • [ISSN] 2214-7500
  • [Journal-full-title] Toxicology reports
  • [ISO-abbreviation] Toxicol Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Keywords] NOTNLM ; CYP3A4 inhibition / HepaRG cells / Hepatotoxicity / HuH-7 cells / Human recombinant CYP3A4 / Isopsoralen / Isopsoralen (PubChem CID: 10658) / Psoralea corylifolia / Psoralen / Psoralen (PubChem CID: 6199)
  •  go-up   go-down


9. Alfonso JH, Bauer A, Bensefa-Colas L, Boman A, Bubas M, Constandt L, Crepy MN, Goncalo M, Macan J, Mahler V, Mijakoski D, Ramada Rodilla JM, Rustemeyer T, Spring P, John SM, Uter W, Wilkinson M, Giménez-Arnau AM: Minimum standards on prevention, diagnosis and treatment of occupational and work-related skin diseases in Europe - position paper of the COST Action StanDerm (TD 1206). J Eur Acad Dermatol Venereol; 2017 Jun;31 Suppl 4:31-43

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimum standards on prevention, diagnosis and treatment of occupational and work-related skin diseases in Europe - position paper of the COST Action StanDerm (TD 1206).
  • BACKGROUND: Skin diseases constitute up to 40% of all notified occupational diseases in most European countries, predominantly comprising contact dermatitis, contact urticaria, and skin cancer.
  • While insufficient prevention of work-related skin diseases (WRSD) is a top-priority problem in Europe, common standards for prevention of these conditions are lacking.
  • OBJECTIVE: To develop common European standards on prevention and management of WRSD and occupational skin diseases (OSD).
  • Workplace exposure assessment of WRSD/OSD requires full labelling of product ingredients on material safety data sheets helping to identify allergens, irritants and skin carcinogens.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 European Academy of Dermatology and Venereology.
  • (PMID = 28656728.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Mark YA, Philip A, Nelson AW, Muspratt A, Aikins S: Safety assessment on microbial and heavy metal concentration in Clarias gariepinus (African catfish) cultured in treated wastewater pond in Kumasi, Ghana. Environ Technol; 2017 Oct 23;:1-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety assessment on microbial and heavy metal concentration in Clarias gariepinus (African catfish) cultured in treated wastewater pond in Kumasi, Ghana.
  • Pond water, sediments and fish tissue (gill, liver, gut and skin) samples from both sources were analyzed for pathogens and heavy metal levels.
  • Significantly higher levels of pathogen contamination were detected in the gut and skin of fish from the WFP than the NWFP.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 29057716.001).
  • [ISSN] 0959-3330
  • [Journal-full-title] Environmental technology
  • [ISO-abbreviation] Environ Technol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; African catfish / Bacterial pathogens / Ghana / aquaculture / heavy metals / wastewater
  •  go-up   go-down


11. Musazzi UM, Franzè S, Minghetti P, Casiraghi A: Emulsion versus nanoemulsion: how much is the formulative shift critical for a cosmetic product? Drug Deliv Transl Res; 2017 May 15;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, nanoemulsions seemed to improve the penetration of active ingredients through the human skin, comparing to conventional emulsion.
  • In this contest, the risk of a higher systemic exposure of consumer to active ingredients, due to the ability of nanoemulsion to enhance permeation, results a critical attribute that should be evaluated for assuring the consumer safety.
  • The aim of this work was the evaluation of how an oil-in-water (O/W) nanoemulsion can influence the in vitro skin permeation profiles of two model active ingredients with different polarity (i.e., caffeine and ethyl ximenynate).
  • Considering such findings, it is worth observing that there is room for reconsidering the risk assessment of nanoemulsion-based cosmetic products.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28508377.001).
  • [ISSN] 2190-3948
  • [Journal-full-title] Drug delivery and translational research
  • [ISO-abbreviation] Drug Deliv Transl Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Caffeine / Cosmetic / Ethyl ximenynate / Nanoemulsion / Risk assessment
  •  go-up   go-down


12. Roberts DW, Aptula A, Api AM: Structure-Potency Relationships for Epoxides in Allergic Contact Dermatitis. Chem Res Toxicol; 2017 Feb 20;30(2):524-531

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epoxides are known or proposed to be involved in skin sensitization in various ways.
  • To date no quantitative mechanistic models (QMMs) are known for skin sensitization potency of this subcategory of S<sub>N</sub>2 electrophiles.
  • The epoxide QMM predicts the potency of a nonepoxide S<sub>N</sub>2 electrophile (predicted EC3, 0.48%; observed EC3, 0.5%), which suggests that it could form the basis for a more general H-polar S<sub>N</sub>2 QMM that could be a valuable tool in skin sensitization risk assessment for this quite extensive and structurally diverse reaction mechanistic domain.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28121139.001).
  • [ISSN] 1520-5010
  • [Journal-full-title] Chemical research in toxicology
  • [ISO-abbreviation] Chem. Res. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Epoxy Compounds
  •  go-up   go-down


13. Shendell DG, Graber JM, Milich LJ, Pratt ME: Assessing Acute Symptoms Related to Occupational Exposures Among Nail Salon Technicians. J Occup Environ Med; 2017 Nov 02;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In 2016, an in-person safety and health survey was conducted.
  • Data were gathered on symptoms, demographics, work history, tobacco use, area and/or task ventilation, use of personal protective equipment (PPE), and safety training.
  • RESULTS: Of the 68 respondents from 40 participating salons whose owners agreed to participate (35% salon-level participation), most were Asian females with a self-reported history of work-associated eye, nose, throat, and skin symptoms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 29099468.001).
  • [ISSN] 1536-5948
  • [Journal-full-title] Journal of occupational and environmental medicine
  • [ISO-abbreviation] J. Occup. Environ. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Derby BM, Codner MA: Evidence-Based Medicine: Face Lift. Plast Reconstr Surg; 2017 Jan;139(1):151e-167e

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 3. Incorporate risk-reduction strategies during preoperative assessment.
  • 6. Incorporate use of valid patient outcomes assessment tools in their practice to facilitate standardized outcomes reporting in the face-lift literature.
  • SUMMARY: Treating the aged face requires an understanding of bone and soft-tissue anatomy, including the analogous lamellar layers of the face and neck, and the techniques designed to restore youthful skin tone and facial contours.
  • [MeSH-minor] Evidence-Based Medicine. Face / anatomy & histology. Facial Nerve / anatomy & histology. Female. Humans. Male. Patient Safety. Postoperative Complications / prevention & control. Preoperative Care

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28027252.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


15. Myhill T, Coulson W, Nixon P, Royal S, McCormack T, Kerrouche N: Use of Supplementary Patient Education Material Increases Treatment Adherence and Satisfaction Among Acne Patients Receiving Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel in Primary Care Clinics: A Multicenter, Randomized, Controlled Clinical Study. Dermatol Ther (Heidelb); 2017 Dec;7(4):515-524

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Other assessments included a subject appreciation questionnaire, a physician questionnaire, and safety.
  • According to the subject appreciation questionnaire, the SEM was more helpful to adhere to treatment (56.7%) versus more visits (32.3%) and A/BPO alone (15.2%), better use the product (70%, 61.3%, and 54.5%, respectively), and better manage skin irritation (53.3%, 48.4%, and 36.4%, respectively).
  • Safety assessment showed fewer treatment-related adverse events in the A/BPO + SEM group.
  • FUNDING: Nestle Skin Health-Galderma R&D.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Patient Prefer Adherence. 2012;6:127-35 [22379363.001]
  • [Cites] J Am Acad Dermatol. 2009 May;60(5):879-80 [19389536.001]
  • [Cites] Dermatol Pract Concept. 2015 Oct 31;5(4):13-6 [26693083.001]
  • [Cites] Eur J Dermatol. 2008 Sep-Oct;18(5):524-6 [18693154.001]
  • [Cites] Am J Clin Dermatol. 2014 Apr;15(2):87-94 [24481999.001]
  • [Cites] Cutis. 2009 Aug;84(2):110-6 [19746769.001]
  • [Cites] Cutis. 2008 Jan;81(1):81-6 [18306854.001]
  • [Cites] Clin Cosmet Investig Dermatol. 2014 Feb 18;7:65-72 [24600239.001]
  • [Cites] J Dermatolog Treat. 2013 Apr;24(2):82-8 [23432428.001]
  • [Cites] Br Med J. 1979 Apr 28;1(6171):1109-10 [156054.001]
  • [Cites] J Am Acad Dermatol. 2007 Nov;57(5):791-9 [17655969.001]
  • [Cites] J Cutan Med Surg. 2009 Jul-Aug;13(4):204-8 [19706228.001]
  • [Cites] Int J Dermatol. 2010 Apr;49(4):448-56 [20465705.001]
  • [Cites] Arch Dermatol. 2011 Oct;147(10):1223-4 [22006146.001]
  • [Cites] J Am Acad Dermatol. 2003 Jul;49(1 Suppl):S1-37 [12833004.001]
  • [Cites] Dermatology. 2011;223(2):174-81 [22025005.001]
  • [Cites] Cutis. 2008 Mar;81(3):278-84 [18441854.001]
  • [Cites] Br J Dermatol. 2009 Nov;161(5):1180-9 [19466959.001]
  • [Cites] Dermatology. 2008;217(4):309-14 [18714158.001]
  • [Cites] Br J Dermatol. 1998 Oct;139 Suppl 52:8-11 [9990414.001]
  • [Cites] J Drugs Dermatol. 2014 Feb;13(2):135-40 [24509962.001]
  • [Cites] J Dtsch Dermatol Ges. 2015 Jun;13(6):557-65 [26018369.001]
  • [Cites] J Am Acad Dermatol. 2007 Jul;57(1):81-3 [17498841.001]
  • [Cites] Dermatology. 2009;218(1):26-32 [18946201.001]
  • (PMID = 29027127.001).
  • [ISSN] 2193-8210
  • [Journal-full-title] Dermatology and therapy
  • [ISO-abbreviation] Dermatol Ther (Heidelb)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; Acne / Adapalene 0.1%/benzoyl peroxide 2.5% gel / Patient adherence / Primary care / Supplementary patient education
  •  go-up   go-down


16. Hoffman LK, Kircik L: Efficacy and Safety of Desoximetasone 0.25% Spray in Adult Atopic Dermatitis Subjects: Pilot Study. J Drugs Dermatol; 2017 Sep 01;16(9):919-922
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and Safety of Desoximetasone 0.25% Spray in Adult Atopic Dermatitis Subjects: Pilot Study.
  • BACKGROUND: Atopic dermatitis (AD) is a chronic, relapsing, inflammatory skin disorder.
  • STUDY DESIGN: A single-center, open labeled pilot study was conducted to investigate the efficacy and safety of desoximetasone 0.25% spray for pruritus in adult atopic dermatitis patients.
  • RESULTS: Twice daily application of desoximetasone 0.25% spray to affected areas resulted in a significant reduction in all outcomes (IGA, pruritus, VAS assessment of pruritus) within 1 week of initiation of treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28915287.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Abruzzo A, Armenise N, Bigucci F, Cerchiara T, Gösser MB, Samorì C, Galletti P, Tagliavini E, Brown DM, Johnston HJ, Fernandes TF, Luppi B: Surfactants from itaconic acid: Toxicity to HaCaT keratinocytes in vitro, micellar solubilization, and skin permeation enhancement of hydrocortisone. Int J Pharm; 2017 May 30;524(1-2):9-15

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surfactants from itaconic acid: Toxicity to HaCaT keratinocytes in vitro, micellar solubilization, and skin permeation enhancement of hydrocortisone.
  • One of the most widely used approaches for improving drug permeation across the stratum corneum barrier of the skin is the use of chemical penetration enhancers, such as surfactants.
  • Assessment of impacts on HaCaT keratinocyte cell viability was used as indicator of their potential to cause skin irritation 24h post exposure (Alamar Blue assay).
  • The effect of different surfactant concentrations (up to ten times the critical micellar concentration, CMC) on hydrocortisone (HC) solubility and permeation through porcine skin was also evaluated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier B.V. All rights reserved.
  • (PMID = 28356226.001).
  • [ISSN] 1873-3476
  • [Journal-full-title] International journal of pharmaceutics
  • [ISO-abbreviation] Int J Pharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Cytotoxicity / Hydrocortisone / Keratinocyte / Micellar solubilization / Skin permeation enhancement / Surfactants
  •  go-up   go-down


18. Munavalli G: A Split-Face Assessment of the Synergistic Potential of Sequential Q-Switched Nd:YAG Laser and 1565 nm Fractional Nonablative Laser Treatment for Facial Rejuvenation in Fitzpatrick Skin Type II-V Patients. J Drugs Dermatol; 2016 Nov 01;15(11):1335-1342
MedlinePlus Health Information. consumer health - Skin Aging.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Split-Face Assessment of the Synergistic Potential of Sequential Q-Switched Nd:YAG Laser and 1565 nm Fractional Nonablative Laser Treatment for Facial Rejuvenation in Fitzpatrick Skin Type II-V Patients.
  • Recent appreciation of the multifactorial pathophysiology of skin aging has led to increased use of parallel treatment regimens.
  • This prospective, split-face, randomized study assessed the safety and efficacy of same-day sequential Q-switched Nd:YAG laser and 1565 nm non-ablative fractional laser (SST) facial rejuvenation treatment in comparison to fractional non-ablative laser (NAFL) treatment only.
  • Immediate skin responses were assessed within 30 minutes of treatment, while wrinkle/elastosis scores, and skin tone and texture were evaluated 1, 3, and 6 months following the final treatment session.
  • Physician-evaluated skin tone and patient ratings of skin texture and overall improvement of the SST-treated side were consistently higher than the contralateral NAFL-treated side.
  • Although the SST regimen failed to demonstrate statistically signi cant clinical superiority over the NAFL regimen, the significantly lower pain levels, consistently higher physician and patient ratings following SST may justify its regular use as a skin rejuvenation technique.
  • [MeSH-major] Cosmetic Techniques. Laser Therapy / methods. Lasers, Solid-State / therapeutic use. Low-Level Light Therapy / methods. Rejuvenation. Skin Aging
  • [MeSH-minor] Aged. Combined Modality Therapy / adverse effects. Female. Follow-Up Studies. Humans. Middle Aged. Pain / etiology. Skin Pigmentation / physiology

  • MedlinePlus Health Information. consumer health - Piercing and Tattoos.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28095544.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. de Cuyper C, Lodewick E, Schreiver I, Hesse B, Seim C, Castillo-Michel H, Laux P, Luch A: Are metals involved in tattoo-related hypersensitivity reactions? A case report. Contact Dermatitis; 2017 Aug 09;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Metal implants and a skin biopsy of a reactive tattoo were analysed for elemental contents by inductively coupled plasma mass spectrometry and synchrotron-based X-ray fluorescence (XRF) spectroscopy.
  • RESULTS: Nickel (Ni) and chromium (Cr) as well as high levels of titanium (Ti) and aluminium were detected in both the skin biopsy and the implants.
  • However, patch tests with an extract of the implants and metallic Ti on the tattooed skin evoked flare-up of the symptoms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
  • (PMID = 28795428.001).
  • [ISSN] 1600-0536
  • [Journal-full-title] Contact dermatitis
  • [ISO-abbreviation] Contact Derm.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; aluminium / chromium / contact allergy / hypersensitivity / metal implant / nickel / osteosynthesis / tattoo allergy / titanium / titanium dioxide
  •  go-up   go-down


20. DuBois JC, Jarratt M, Beger BB, Bradshaw M, Powala CV, Shanler SD: A-101, a Proprietary Topical Formulation of High-Concentration Hydrogen Peroxide Solution: A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of the Dose-Response Profile in Subjects With Seborrheic Keratosis of the Face. Dermatol Surg; 2017 Sep 04;
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Seborrheic keratosis (SK) is a common benign skin tumor, yet no topical treatments are approved in the United States.
  • The primary efficacy assessment was the Physician's Lesion Assessment (PLA), a validated 4-ordinal scale.
  • Local skin reactions were predominantly mild and transient.
  • A-101 solution had a favorable safety and tolerability profile at both concentrations.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28902028.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Casati S, Aschberger K, Barroso J, Casey W, Delgado I, Kim TS, Kleinstreuer N, Kojima H, Lee JK, Lowit A, Park HK, Régimbald-Krnel MJ, Strickland J, Whelan M, Yang Y, Zuang V: Standardisation of defined approaches for skin sensitisation testing to support regulatory use and international adoption: position of the International Cooperation on Alternative Test Methods. Arch Toxicol; 2017 Nov 10;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Standardisation of defined approaches for skin sensitisation testing to support regulatory use and international adoption: position of the International Cooperation on Alternative Test Methods.
  • Skin sensitisation is the regulatory endpoint that has been at the centre of concerted efforts to replace animal testing in recent years, as demonstrated by the Organisation for Economic Co-operation and Development (OECD) adoption of five non-animal methods addressing mechanisms under the first three key events of the skin sensitisation adverse outcome pathway.
  • Nevertheless, the currently adopted methods, when used in isolation, are not sufficient to fulfil regulatory requirements on the skin sensitisation potential and potency of chemicals comparable to that provided by the regulatory animal tests.
  • With the aim to further enhance regulatory consideration and adoption of defined approaches, the European Union Reference Laboratory for Alternatives to Animal testing in collaboration with the International Cooperation on Alternative Test Methods hosted, on 4-5 October 2016, a workshop on the international regulatory applicability and acceptance of alternative non-animal approaches, i.e., defined approaches, to skin sensitisation assessment of chemicals used in a variety of sectors.
  • Potential assessment criteria were defined for a systematic evaluation of existing defined approaches that would facilitate their translation into international standards, e.g., into a performance-based Test Guideline.
  • Informed by the discussions at the workshop, the ICATM members propose practical ways to further promote the regulatory use and facilitate adoption of defined approaches for skin sensitisation assessments.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 29127450.001).
  • [ISSN] 1432-0738
  • [Journal-full-title] Archives of toxicology
  • [ISO-abbreviation] Arch. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; Adverse outcome pathway / Alternative methods / Defined approaches / International standards / Skin sensitisation
  •  go-up   go-down


22. Politi Y, Levi A, Lapidoth M: Integrated Cooling-Vacuum-Assisted Non-Fractional 1540 nm Erbium:Glass Laser is Effective in Treating Acne Scars. J Drugs Dermatol; 2016 Nov 01;15(11):1359-1363
MedlinePlus Health Information. consumer health - Scars.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mid-infrared laser skin interaction is characterized by its modest absorption in water and nite penetration to the mid-dermis.
  • OBJECTIVES: To evaluate the safety and efficacy of acne scars treatment using an integrated cooling-vacuum-assisted 1540 nm Erbium: Glass Laser.
  • Average improvement was 3.9 and 4.1 points on the quartile scale used for outcome assessment 1 and 3 months following the last session, respectively.

  • MedlinePlus Health Information. consumer health - Acne.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28095548.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Hena KM, Yip J, Jaber N, Goldfarb D, Fullam K, Cleven K, Moir W, Zeig-Owens R, Webber MP, Spevack DM, Judson MA, Maier L, Krumerman A, Aizer A, Spivack SD, Berman J, Aldrich TK, Prezant DJ, FDNY Sarcoidosis Clinical Research Group*: Clinical Course of Sarcoidosis in World Trade Center-Exposed Firefighters. Chest; 2017 Oct 21;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For each participant, the World Association of Sarcoidosis and Other Granulomatous Diseases organ assessment tool was used to categorize the sarcoidosis involvement of each organ system at time of diagnosis and at follow-up.
  • Few subjects had ocular (5%) or skin (2%) involvement, and none had beryllium sensitization.
  • Our results also support the need for advanced cardiac screening in asymptomatic patients with strenuous, stressful, public safety occupations, given the potential fatality of a missed diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.
  • (PMID = 29066387.001).
  • [ISSN] 1931-3543
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL119326; United States / NIOSH CDC HHS / OH / U01 OH011300
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; World Trade Center / clinical course / firefighters / sarcoidosis
  • [Investigator] Christodoulou V; Hena Z; Plotycia SM; Soghier I; Gritz D; Acuna DS; Weiden MD; Nolan A; Diaz K; Ortiz V; Kelly K
  •  go-up   go-down


24. Tolcher AW, Baird RD, Patnaik A, Moreno Garcia V, Papadopoulos KP, Garrett CR, Olmos D, Shannon KA, Zazulina V, Rubin EH, Smith IC, Ryan J, Smith PD, Taylor A, Learoyd M, Lupinacci L, Yan L, De Bono JS: A phase I dose-escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors. J Clin Oncol; 2011 May 20;29(15_suppl):3004

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objectives of this phase I study were to examine the safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary antitumor activity of the novel combination of MK-2206 with selumetinib.
  • In the MK-2206 QOD dosing schedule, dose-limiting Grade 3 macular skin rash was reported in 2/3 evaluable patients at MK-2206 45 mg QOD with selumetinib 75mg BID; the tolerable dose was MK-2206 45 mg QOD with selumetinib 75 mg QD.
  • Preliminary assessment of PK/PD data suggest no apparent drug-drug interactions with the PK profile of each drug administered in this combination.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28022185.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Ratain MJ, Flaherty KT, Stadler WM, O'Dwyer P, Kaye S, Xiong H, Patnaik A, Gore M, Lee RJ, Eisen T: Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT). J Clin Oncol; 2004 Jul 15;22(14_suppl):4501

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Typical drug-related toxicities were hand-foot skin reaction, rash, fatigue, diarrhea, anorexia and hypertension.
  • Of the 112 pts with RCC, 65 pts have reached the initial 12-week assessment (63 evaluable for response).
  • The randomized portion will provide information about BAY's disease-stabilizing effect and long-term safety, in particular in pts with RCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016014.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Malisch R, Denison MS, Fiedler H, Fürst P, Hoogenboom RLAP, Schaechtele A, Schrenk D, van den Berg M: Do PCDD/PCDF standard solutions used in dioxin analysis pose a risk as potentially acutely toxic to lab personnel? Chemosphere; 2017 Oct;185:489-498
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Laboratory safety requires protecting personnel from chemical exposures.
  • As worst case exposure scenario during routine laboratory work it was assumed that a dose of 100 ng TCDD gets onto the skin and is absorbed.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28715759.001).
  • [ISSN] 1879-1298
  • [Journal-full-title] Chemosphere
  • [ISO-abbreviation] Chemosphere
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzofurans; 0 / Polychlorinated Dibenzodioxins
  • [Keywords] NOTNLM ; Acute toxicity / Laboratory incidents / PCDD/PCDF / Safety partnerships / Standard solutions
  •  go-up   go-down


27. Park M, Naidoo AA, Burns A, Choi JK, Gatfield KM, Vidgeon-Hart M, Bae IH, Lee CS, Choi G, Powell AJ, Park YH, Fagg R: Do TRPV1 antagonists increase the risk for skin tumourigenesis? A collaborative in vitro and in vivo assessment. Cell Biol Toxicol; 2017 Aug 16;
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do TRPV1 antagonists increase the risk for skin tumourigenesis? A collaborative in vitro and in vivo assessment.
  • However, little is known about the long-term physiologic effects of TRPV1 blockade in the skin.
  • In vitro and in vivo studies suggested that the potent TRPV1 competitive antagonist AMG-9810 promoted proliferation in N/TERT1 cells (telomerase-immortalised primary human keratinocytes 1) and tumour development in mouse skin that was mediated through EGFR/Akt/mTOR signalling.
  • We attempted to reproduce the reported in vitro and in vivo findings to further explore this hypothesis to understand the underlying mechanism and the risk associated with TRPV1 antagonism in the skin.
  • We were also unable to demonstrate skin tumour promotion or underlying molecular mechanisms involved in the EGFR/Akt/mTOR signalling pathway in a single-dose and two-stage carcinogenesis mouse study treated with TRPV1 antagonists.
  • In conclusion, our data suggest that inhibiting the pharmacological function of TRPV1 in skin by specific antagonists has not been considered to be indicative of skin tumour development.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28815372.001).
  • [ISSN] 1573-6822
  • [Journal-full-title] Cell biology and toxicology
  • [ISO-abbreviation] Cell Biol. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; EGFR/Akt/mTOR / Human keratinocytes / Skin tumour / TRPV1
  •  go-up   go-down


28. Thotakura N, Kumar P, Wadhwa S, Raza K, Katare P: Dermatokinetics as an Important Tool to Assess the Bioavailability of Drugs by Topical Nanocarriers. Curr Drug Metab; 2017;18(5):404-411

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To estimate the amount of drug delivery to skin, the scientists have now established techniques for separation of skin layers for the determination of drug concentrations.
  • This forms the basis of pharmacokinetics of drug(s) in skin, i.e., dermatokinetics.
  • Assessment of bioavailability helps in determination of safety and efficacy of topical formulations.
  • CONCLUSION: As the methods used for determination of pharmacokinetics of oral and intravenous formulations are not useful for dermatokinetic assessment, various methods like tape stripping, microdialysis and vasoconstrictor assays are being used for dermatokinetic assessment.
  • These methods are not only useful to determine the drug concentrations in skin layers, but can also be used to correlate the toxic effects of xenobiotics.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
  • (PMID = 28266274.001).
  • [ISSN] 1875-5453
  • [Journal-full-title] Current drug metabolism
  • [ISO-abbreviation] Curr. Drug Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Pharmacokinetics / confocal microscopy / follicular drug penetration / micro dialysis / tape stripping / trypsin digestion / vasoconstrictor assay
  •  go-up   go-down


29. O'Reilly EM, Roach J, Miller P, Yu KH, Tjan C, Rosano M, Krause S, Avery W, Wolf J, Flaherty K, Nix D, Ryan DP: Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results. Oncologist; 2017 Dec;22(12):1429-e139

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results.
  • LESSONS LEARNED: Despite the compelling preclinical rationale of evaluating the genetically engineered heparin derivative, necuparanib, combined with standard therapy in metastatic pancreas adenocarcinoma, the results were ultimately disappointing.Safety was documented, although dose escalation was limited by the number of subcutaneous injections, the potential for skin toxicity (cellulitis), and low-level anticoagulant effect.
  • This trial assessed the safety, pharmacokinetics (PK), pharmacodynamics, and initial efficacy of necuparanib combined with gemcitabine ± nab-paclitaxel in patients with metastatic pancreatic cancer.
  • Given a cellulitis event and mild activated partial thromboplastin time increases at 6 mg/kg, the 5 mg/kg dose was considered the MTD and selected for further assessment in phase II.
  • CONCLUSION: Acceptable safety and encouraging signals of activity in patients with metastatic pancreatic cancer receiving necuparanib, nab-paclitaxel, and gemcitabine were demonstrated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © AlphaMed Press; the data published online to support this summary is the property of the authors.
  • (PMID = 29158367.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Barbero AM, Frasch HF: Effect of stratum corneum heterogeneity, anisotropy, asymmetry and follicular pathway on transdermal penetration. J Control Release; 2017 Aug 28;260:234-246

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A quantitative and thorough study of skin permeation is essential for chemical exposure assessment and transdermal delivery of drugs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier B.V.
  • (PMID = 28596104.001).
  • [ISSN] 1873-4995
  • [Journal-full-title] Journal of controlled release : official journal of the Controlled Release Society
  • [ISO-abbreviation] J Control Release
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Corneocyte / Diffusion / Lag time / Lipid bilayers / Partition coefficient / Skin appendages
  •  go-up   go-down


31. Tozzi P, Siniscalchi G, Ferrari E, Kirsch M, Hayoz D: Percutaneous increase of mitral leaflet coaptation length after mitral valve repair: results from a preclinical study. Interact Cardiovasc Thorac Surg; 2017 Dec 13;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We conducted preclinical studies to assess the in vivo feasibility of the procedure and the safety of the postimplant deformable mitral ring.
  • The connection line exited the left atrium and reached the skin.
  • Epicardial echocardiography allowed assessment of valve competence, leaflet CL, the mitral valve area and the mitral valve gradient.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 29244156.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Mitral regurgitation / Mitral ring / Mitral valve repair
  •  go-up   go-down


32. Friedman PM, Tolkachjov SN, Geddes ER, Tillman KA, Zachary CB: TRASER: An innovative device for the treatment of nasal telangiectasias. Lasers Surg Med; 2017 Aug;49(6):625-631

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the safety and efficacy of a novel configurable device in the treatment of nasal telangiectasias.
  • METHODS: Fifteen subjects aged 42-73 with Fitzpatrick skin types I and II were treated for nasal telangiectasias of various sizes.
  • Efficacy was measured by blinded analysis of pre and post images and self-assessment by the subjects.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 Wiley Periodicals, Inc.
  • [ErratumIn] Lasers Surg Med. 2017 Oct;49(8):787 [28921617.001]
  • (PMID = 28382712.001).
  • [ISSN] 1096-9101
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; TRASER / Total Reflection Amplification of Spontaneous Emission Radiation / pulse dye laser / pyrromethene / telangiectasias / total internal reflection / tunable wavelength / variable pulse duration
  •  go-up   go-down


33. Czaplik M, Hochhausen N, Dohmeier H, Pereira CB, Rossaint R: Development of a "Thermal-Associated Pain Index" score using infrared-thermography for objective pain assessment. Conf Proc IEEE Eng Med Biol Soc; 2017 Jul;2017:3831-3834

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of a "Thermal-Associated Pain Index" score using infrared-thermography for objective pain assessment.
  • Without any doubt, research in biomedical engineering and anesthesiology achieved diverse ground-breaking successes for the sake of patient safety and for optimization of medical treatment in the last decades.
  • However, assessment of pain still relies on self-reporting of the patient using a Numeric Rating Scale ranging from 0 to 10.
  • Skin conductance, heart rate variability and peripheral perfusion, among others, were used to develop new algorithms and devices.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 29060733.001).
  • [ISSN] 1557-170X
  • [Journal-full-title] Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference
  • [ISO-abbreviation] Conf Proc IEEE Eng Med Biol Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Martí-Bonmatí L, Martí-Bonmatí E: Retention of gadolinium compounds used in magnetic resonance imaging: a critical review and the recommendations of regulatory agencies. Radiologia; 2017 Nov - Dec;59(6):469-477

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Spanish Agency for Drugs and Healthcare Products (AEMPS), based on the recommendations of the European Committee for Risk Assessment in Pharmacovigilance, established on 13 March 2017 that linear gadolinium-based MR contrast media, such as MultiHance, Omniscan, Magnevist (currently not marketed) and Optimark (no longer marketed in Spain), the clinical benefits do not outweigh the potential risks derived from their use.
  • All existing gadolinium contrasts agents have a distribution phase with tissue retention, due to a very slow exchange, in the interstitium of bone, skin, kidney, brain and other organs.
  • Since the safety profiles are mainly related to the interstitial retention space in the tissues, it does not seem justified to actually exclude contrast media that do not have cases related to the NSF.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 SERAM. Publicado por Elsevier España, S.L.U. All rights reserved.
  • (PMID = 29110904.001).
  • [ISSN] 1578-178X
  • [Journal-full-title] Radiologia
  • [ISO-abbreviation] Radiologia
  • [Language] eng; spa
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Keywords] NOTNLM ; Contrast media / Gadolinio / Gadolinium / Magnetic resonance / Medios de contraste / Resonancia magnética / Retención tisular / Tissue retention
  •  go-up   go-down


35. Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Belousova E, Frost MD, Sauter M, Brakemeier S, de Vries PJ, Berkowitz N, Voi M, Peyrard S, Budde K: Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study. PLoS One; 2017;12(8):e0180939
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The key secondary end point was safety.
  • Subependymal giant cell astrocytoma lesion response was achieved in 48% of patients and skin lesion response in 68% of patients.
  • The overall risk/benefit assessment supports the use of everolimus as a viable treatment option for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis.

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Neurol. 2013 Oct;49(4):255-65 [24053983.001]
  • [Cites] J Med Genet. 1996 Jun;33(6):480-4 [8782048.001]
  • [Cites] Curr Neuropharmacol. 2012 Dec;10(4):404-15 [23730262.001]
  • [Cites] Neurology. 2013 Feb 5;80(6):574-80 [23325902.001]
  • [Cites] Radiology. 2002 Oct;225(1):78-82 [12354988.001]
  • [Cites] J Urol. 1998 Jul;160(1):141-5 [9628635.001]
  • [Cites] N Engl J Med. 2006 Sep 28;355(13):1345-56 [17005952.001]
  • [Cites] Nephrol Dial Transplant. 2016 Jan;31(1):111-9 [26156073.001]
  • [Cites] Anticancer Drugs. 2015 Apr;26(4):437-42 [25719621.001]
  • [Cites] BJU Int. 2010 Jan;105(1):101-6 [19493268.001]
  • [Cites] Kidney Int. 2006 Nov;70(10):1777-82 [17003820.001]
  • [Cites] BJU Int. 2004 Oct;94(6):853-7 [15476522.001]
  • [Cites] Ann N Y Acad Sci. 1991;615:125-7 [2039137.001]
  • [Cites] Lancet. 2013 Jan 12;381(9861):125-32 [23158522.001]
  • [Cites] N Engl J Med. 2010 Nov 4;363(19):1801-11 [21047224.001]
  • [Cites] Lancet. 2008 Aug 23;372(9639):657-68 [18722871.001]
  • [Cites] AJR Am J Roentgenol. 2015 Aug;205(2):292-301 [26204278.001]
  • [Cites] Am J Physiol Renal Physiol. 2014 Sep 1;307(5):F560-70 [24920756.001]
  • [Cites] Am J Kidney Dis. 2012 Feb;59(2):276-83 [22130643.001]
  • [Cites] N Engl J Med. 2011 Apr 28;364(17):1595-606 [21410393.001]
  • [Cites] Ann Neurol. 2015 Dec;78(6):929-38 [26381530.001]
  • [Cites] Am J Kidney Dis. 2015 Oct;66(4):638-45 [26165440.001]
  • [Cites] J Urol. 2002 Oct;168(4 Pt 1):1315-25 [12352384.001]
  • [Cites] Lancet. 2013 Mar 9;381(9869):817-24 [23312829.001]
  • [Cites] Ann Intern Med. 2006 Aug 15;145(4):247-54 [16908915.001]
  • (PMID = 28792952.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 9HW64Q8G6G / Everolimus
  •  go-up   go-down


36. Jaffray D, Mutic S, Fallone B, Raaymakers B: MO-A-WAB-01: MRI-Guided Radiation Therapy. Med Phys; 2013 Jun;40(6Part23):390

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The concept of integrating a magnetic resonance imaging (MRI) scanner with a therapy radiation source, either a therapy linear accelerator (linac) or <sup>60</sup> Co, emerged as a feasible novel approach for MRI-guided radiation therapy (i.e.
  • MRI offers the capability to visualize soft-tissue as well as to perform physiological assessment of healthy and tumor tissues.
  • Multiple interdependent issues need to be resolved in order to achieve the optimal operation of the MRI scanner and the radiation source(s) such as: a) radiofrequency (RF) interference, b) magnetic field coupling, c) perturbation of the dose deposited in tissue due to the presence of an external magnetic field, and d) escalation of patient skin dose.
  • They will also discuss key aspects related to the clinical implementation of their systems such as safety, applications, workflows, quality control, staffing models for supporting the infrastructure, and preliminary data.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2013 American Association of Physicists in Medicine.
  • (PMID = 28518368.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Dosimetry / Linear accelerators / Magnetic fields / Magnetic resonance / Magnetic resonance imaging / Medical imaging / Radiation therapy / Radiation treatment / Radiotherapy sources / Tissues
  •  go-up   go-down


37. Bhattacharyya A, Jain N, Prasad S, Jain S, Yadav V, Ghosh S, Sengupta S: Evaluation of therapeutic potential of VB-001, a leave-on formulation, for the treatment of moderate adherent dandruff. BMC Dermatol; 2017 May 03;17(1):5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to determine the efficacy and skin safety of VB-001 antidandruff leave-on formulation in comparison with marketed antidandruff ZPTO shampoo in patients with moderate adherent dandruff of the scalp.
  • The efficacy of each product was evaluated by comparing proportion of subjects who have shown reduction in flaking by ASFS (adherent scalp flaking score) and pruritus by IGA (investigator global assessment) score.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 1975 Jun;64(6):401-5 [237965.001]
  • [Cites] J Clin Aesthet Dermatol. 2011 Sep;4(9):22-42 [21938268.001]
  • [Cites] J Investig Dermatol Symp Proc. 2005 Dec;10(3):194-7 [16382662.001]
  • [Cites] J Investig Dermatol Symp Proc. 2005 Dec;10(3):295-7 [16382685.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18730-5 [18000048.001]
  • [Cites] Int J Cosmet Sci. 2006 Oct;28(5):311-8 [18489295.001]
  • [Cites] Br J Dermatol. 1984 Aug;111(2):235-42 [6235835.001]
  • [Cites] Indian J Dermatol. 2010 Apr-Jun;55(2):130-4 [20606879.001]
  • [Cites] Int J Cosmet Sci. 2012 Aug;34(4):298-306 [22515370.001]
  • [Cites] J Cosmet Dermatol. 2010 Sep;9(3):202-10 [20883293.001]
  • [Cites] J Am Acad Dermatol. 2001 Dec;45(6):897-903 [11712036.001]
  • [Cites] Contact Dermatitis. 2002 Jan;46(1):6-12 [11918580.001]
  • [Cites] Mycoses. 2015 Apr;58(4):215-9 [25676074.001]
  • [Cites] Crit Care Med. 1999 Sep;27(9):1781-6 [10507598.001]
  • [Cites] Arch Dermatol Res. 2002 Jul;294(5):221-30 [12115025.001]
  • (PMID = 28468620.001).
  • [ISSN] 1471-5945
  • [Journal-full-title] BMC dermatology
  • [ISO-abbreviation] BMC Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Anti-fungals / Dandruff / Malassezia / Scalp
  •  go-up   go-down


38. Guarneri A, Cioni M, Rongioletti F: High-dose intravenous immunoglobulin therapy for scleromyxoedema: a prospective open-label clinical trial using an objective score of clinical evaluation system. J Eur Acad Dermatol Venereol; 2017 Jul;31(7):1157-1160

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the safety and efficacy of high-dose intravenous immunoglobulin (IVIg) for the management of scleromyxoedema prospectively using an objective score.
  • The patients were followed-up to a minimum of 6 months, and their disease activity and response to treatment were assessed using the Physician's Global Assessment of disease severity (PGA) and a modified objective skin scoring system for patients with scleroderma (modified Rodnan score system for scleromyxoedema or mRSSS).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 European Academy of Dermatology and Venereology.
  • (PMID = 28370513.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


39. Anukunwithaya T, Tantisira MH, Tantisira B, Khemawoot P: Pharmacokinetics of a Standardized Extract of Centella asiatica ECa 233 in Rats. Planta Med; 2017 May;83(8):710-717

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ECa 233, a standardized extract of <i>Centella asiatica</i>, has been found to exhibit various positive neurological effects and to have a good safety profile.
  • The results showed that all animals had a good tolerability for ECa 233, whereas madecassic and asiatic acids were found in negligible amounts after pharmacokinetic assessment.
  • Both triterpenoids were extensively distributed in the brain, stomach, and skin within 1 h and remained there for at least 4 h after dosing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart · New York.
  • (PMID = 27992940.001).
  • [ISSN] 1439-0221
  • [Journal-full-title] Planta medica
  • [ISO-abbreviation] Planta Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / ECa 233 extract; 0 / Plant Extracts; 0 / Triterpenes; 34540-22-2 / madecassoside; PKO39VY215 / asiaticoside
  •  go-up   go-down


40. Ahn MJ, Kim DW, Cho BC, Kim SW, Lee JS, Ahn JS, Kim TM, Lin CC, Kim HR, John T, Kao S, Goldman JW, Su WC, Natale R, Rabbie S, Harrop B, Overend P, Yang Z, Yang JC: Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. Lancet Respir Med; 2017 Nov;5(11):891-902
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.
  • We aimed to assess the safety, tolerability, pharmacokinetics, and efficacy of AZD3759 in patients with EGFR-mutant NSCLC with brain and leptomeningeal metastases.
  • The primary objective was safety and tolerability, with severity of adverse events assessed with the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 4.03.
  • Dose-limiting toxic effects occurred in two (67%) of three patients who received 500 mg twice a day in the dose-escalation phase (grade 3 acne [n=1] and intolerable grade 2 mucosal inflammation [n=1]); hence, doses of 200 mg and 300 mg twice a day were selected for further assessment in the dose-expansion phase.
  • Drug-related skin and gastrointestinal disorders of any grade occurred in 35 (92%) and 29 (76%) patients in the dose-expansion phase, respectively, and led to treatment discontinuation in one (4%) patient treated with 200 mg twice a day (grade 3 increase of alanine aminotransferase and aspartate aminotransferase) and two (13%) patients given 300 mg twice a day (grade 3 diarrhoea [n=1] and grade 3 skin rash [n=1]).
  • Grade 3 skin and gastrointestinal disorders occurred in four (17%) and two (9%) patients, respectively, at a dose of 200 mg twice a day, and in six (40%) and four (27%) patients, respectively, at a dose of 300 mg twice a day.
  • INTERPRETATION: AZD3759 at a dose of 200 mg twice daily showed a tolerable safety profile in patients with NSCLC and CNS metastases who had either never received a tyrosine kinase inhibitor or who had been pretreated with a tyrosine kinase inhibitor.
  • The good penetration of the blood-brain barrier by AZD3759, and its promising clinical activity, support further assessment of this compound in studies.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 29056570.001).
  • [ISSN] 2213-2619
  • [Journal-full-title] The Lancet. Respiratory medicine
  • [ISO-abbreviation] Lancet Respir Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


41. Pierce CE, Bouri K, Pamer C, Proestel S, Rodriguez HW, Van Le H, Freifeld CC, Brownstein JS, Walderhaug M, Edwards IR, Dasgupta N: Evaluation of Facebook and Twitter Monitoring to Detect Safety Signals for Medical Products: An Analysis of Recent FDA Safety Alerts. Drug Saf; 2017 Apr;40(4):317-331

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of Facebook and Twitter Monitoring to Detect Safety Signals for Medical Products: An Analysis of Recent FDA Safety Alerts.
  • METHODS: A retrospective analysis of public Facebook and Twitter data was conducted for 10 recent FDA postmarketing safety signals at the drug-event pair level with six negative controls.
  • Drug safety physicians conducted a manual review to determine causality using World Health Organization-Uppsala Monitoring Centre (WHO-UMC) assessment criteria.
  • Of these, 13 posts were selected for causality assessment of product-event pairs.
  • Clinical assessment revealed that posts had sufficient information to warrant further investigation for two possible product-event associations: dronedarone-vasculitis and Banana Boat Sunscreen--skin burns.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Expert Opin Drug Saf. 2015;14(12):1845-53 [26436834.001]
  • [Cites] J Biomed Inform. 2015 Jun;55:73-81 [25817970.001]
  • [Cites] Patient Prefer Adherence. 2015 Jan 23;9:173-84 [25670886.001]
  • [Cites] Drug Saf. 2014 Oct;37(10):761-4 [25096955.001]
  • [Cites] J Med Internet Res. 2015 Jul 10;17(7):e171 [26163365.001]
  • [Cites] J Biomed Inform. 2016 Feb;59:42-8 [26610385.001]
  • [Cites] Nat Rev Rheumatol. 2015 Feb;11(2):119-23 [25314016.001]
  • [Cites] J Biomed Inform. 2011 Dec;44(6):989-96 [21820083.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2007 Oct;16(10):1161-6 [17486665.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2013 Mar;22(3):256-62 [23322591.001]
  • [Cites] J Am Board Fam Pract. 2004 Mar-Apr;17(2):142-9 [15082674.001]
  • [Cites] J Biomed Inform. 2015 Apr;54:202-12 [25720841.001]
  • [Cites] J Clin Pharm Ther. 2014 Feb;39(1):53-5 [24304185.001]
  • [Cites] Drug Saf. 2011 Apr 1;34(4):267-71 [21417499.001]
  • [Cites] Methods Inf Med. 2013;52(2):152-9 [23450374.001]
  • [Cites] Drug Saf. 2016 May;39(5):443-54 [26798054.001]
  • [Cites] Eur J Clin Pharmacol. 2013 Feb;69(2):209-15 [22688722.001]
  • [Cites] Clin Pharmacol Ther. 2014 Aug;96(2):239-46 [24713590.001]
  • [Cites] Br J Clin Pharmacol. 2015 Oct;80(4):910-20 [26147850.001]
  • [Cites] Drug Saf. 2014 Aug;37(8):629-37 [25027671.001]
  • [Cites] Adv Psychobiol. 1974;2:297-312 [4476178.001]
  • [Cites] N Z Med J. 2014 Aug 29;127(1401):69-81 [25225758.001]
  • [Cites] Drug Saf. 2014 May;37(5):343-50 [24777653.001]
  • [Cites] J Biomed Inform. 2015 Feb;53:196-207 [25451103.001]
  • [Cites] J Med Internet Res. 2007 Feb 28;9(1):e4 [17478413.001]
  • [Cites] J Med Internet Res. 2011 May 17;13(2):e37 [21586386.001]
  • [Cites] N Engl J Med. 2009 May 21;360(21):2153-5, 2157 [19423867.001]
  • [Cites] J Addict Dis. 2015;34(4):303-10 [26364675.001]
  • [Cites] Br J Clin Pharmacol. 1996 Oct;42(4):423-9 [8904613.001]
  • [Cites] Br J Clin Pharmacol. 2015 Oct;80(4):878-88 [26271492.001]
  • [Cites] J Biomed Inform. 2015 Apr;54:230-40 [25688695.001]
  • [Cites] J Am Med Inform Assoc. 2015 May;22(3):671-81 [25755127.001]
  • [Cites] Drug Saf. 1999 Feb;20(2):95-107 [10082068.001]
  • [Cites] Clin Pharmacol Ther. 2014 Aug;96(2):149-50 [25056395.001]
  • [Cites] Drug Saf. 2015 Oct;38(10):921-30 [26242616.001]
  • [Cites] Res Social Adm Pharm. 2014 Nov-Dec;10(6):896-903 [24603135.001]
  • [Cites] Trends Pharmacol Sci. 2013 Jul;34(7):357-8 [23759353.001]
  • [Cites] J Antimicrob Chemother. 2014 Sep;69(9):2568-72 [24862092.001]
  • [Cites] AMIA Annu Symp Proc. 2014 Nov 14;2014:924-33 [25954400.001]
  • [Cites] J Nerv Ment Dis. 1972 Nov;155(5):363-5 [5082173.001]
  • [CommentIn] Drug Saf. 2017 Aug;40(8):755 [28425072.001]
  • (PMID = 28044249.001).
  • [ISSN] 1179-1942
  • [Journal-full-title] Drug safety
  • [ISO-abbreviation] Drug Saf
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  •  go-up   go-down


42. Cao Z, Wang M, Chen Q, Zhang Y, Dong W, Yang T, Yan G, Zhang X, Pi Y, Xi B, Bu Q: Preliminary assessment on exposure of four typical populations to potentially toxic metals by means of skin wipes under the influence of haze pollution. Sci Total Environ; 2018 Feb 01;613-614:886-893

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary assessment on exposure of four typical populations to potentially toxic metals by means of skin wipes under the influence of haze pollution.
  • To investigate the exposure risk of human beings to nine potentially toxic metals (PTMs), namely, Cu, Cr, Zn, As, Cd, Pb, Ni, Mn, and Co, skin wipe samples were collected from four types of populations, namely, children, undergraduates, security guards, and professional drivers, under different haze pollution levels in Xinxiang, China by using Ghost wipes.
  • Generally, PTM contamination in skin wipes collected during a light haze pollution level was generally higher than that during a heavy haze pollution level, but PTM contamination was comparable between the two haze pollution levels for children.
  • Non-carcinogenic exposure risks to As, Cd, and Pb for all populations were higher than those for the other six elements but all of them were within the acceptable safety threshold, indicating no apparent non-carcinogenic risk.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier B.V. All rights reserved.
  • (PMID = 28946377.001).
  • [ISSN] 1879-1026
  • [Journal-full-title] The Science of the total environment
  • [ISO-abbreviation] Sci. Total Environ.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Dermal exposure / Dust / Exposure assessment / Haze levels / Potentially toxic metal
  •  go-up   go-down


43. Xiong J, Chiu Y, Pradhan RS, Li X, Li X, Carlson DM, Awni W: Assessment of the effect of ethnicity on linifanib tolerability and pharmacokinetics in patients with cancer. J Clin Oncol; 2011 May 20;29(15_suppl):e13082

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of the effect of ethnicity on linifanib tolerability and pharmacokinetics in patients with cancer.
  • The aim of this assessment was to evaluate the impact of ethnicity on linifanib tolerability and pharmacokinetics (PK) in cancer patients.
  • The impact of ethnicity on tolerability was assessed by evaluating significance of ethnicity on the exposure-safety relationship.
  • Logistic regression analysis was conducted to construct the exposure-safety relationship for eight common adverse events (hypertension, asthenia, GI-abdominal disorder, diarrhea, skin toxicity 1, skin toxicity 2, proteinuria and anorexia).
  • RESULTS: The exposure-safety response analysis showed that ethnicity was not a significant factor influencing the exposure-safety response relationship for any of the tested adverse events.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28019935.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Thomas KS, Bradshaw LE, Sach TH, Cowdell F, Batchelor JM, Lawton S, Harrison EF, Haines RH, Ahmed A, Dean T, Burrows NP, Pollock I, Buckley HK, Williams HC, Llewellyn J, Crang C, Grundy JD, Guiness J, Gribbin A, Wake EV, Mitchell EJ, Brown SJ, Montgomery AA: Randomised controlled trial of silk therapeutic garments for the management of atopic eczema in children: the CLOTHES trial. Health Technol Assess; 2017 Apr;21(16):1-260
Genetic Alliance. consumer health - Eczema.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Atopic eczema (AE) is a chronic, itchy, inflammatory skin condition that affects the quality of life of children and their families.
  • Secondary outcomes - patient-reported eczema symptoms (Patient Oriented Eczema Measure); global assessment of severity (Investigator Global Assessment); quality of life of the child (Atopic Dermatitis Quality of Life, Child Health Utility - 9 Dimensions), family (Dermatitis Family Impact Questionnaire) and main carer (EuroQoL-5 Dimensions-3 Levels); use of standard eczema treatments (e.g. emollients, topical corticosteroids); and cost-effectiveness.
  • Safety outcomes - number of skin infections and hospitalisations for AE.
  • Skin infections occurred in 39 out of 141 (28%) and 36 out of 142 (25%) participants for standard care and silk clothing groups, respectively.
  • FUNDING: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in <i>Health Technology Assessment</i>; Vol.
  • [MeSH-minor] Child, Preschool. Chronic Disease. Cost-Benefit Analysis. Humans. Qualitative Research. Quality of Life. Severity of Illness Index. Standard of Care. Surveys and Questionnaires. Technology Assessment, Biomedical

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28409557.001).
  • [ISSN] 2046-4924
  • [Journal-full-title] Health technology assessment (Winchester, England)
  • [ISO-abbreviation] Health Technol Assess
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Silk
  •  go-up   go-down


45. Parekh M, Ramaiah G, Pashilkar P, Ramanujam R, Johnston P, Ilag LL: A pilot single centre, double blind, placebo controlled, randomized, parallel study of Calmagen® dermaceutical cream and lotion for the topical treatment of tinea and onychomycosis. BMC Complement Altern Med; 2017 Sep 18;17(1):464
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study aimed to establish the fungicidal, efficacy and safety profile of Calmagen® dermaceutical cream and lotion containing AMYCOT® as a topical treatment in patients with severe to very severe presentations of fungal skin (tinea) and nail infections (onychomycosis).
  • Clinical cure was defined as Investigator Global Assessment (IGA) response of 'cleared' or 'excellent'.

  • MedlinePlus Health Information. consumer health - Tinea Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cochrane Database Syst Rev. 2014 Aug 04;(8):CD009992 [25090020.001]
  • [Cites] An Bras Dermatol. 2010 Sep-Oct;85(5):657-67 [21152790.001]
  • [Cites] Skinmed. 2005 Sep-Oct;4(5):305-10 [16282753.001]
  • [Cites] J Am Podiatr Med Assoc. 2014 Sep-Oct;104(5):479-85 [25275736.001]
  • [Cites] Indian J Dermatol Venereol Leprol. 2008 May-Jun;74(3):226-9 [18583788.001]
  • [Cites] J Clin Lab Anal. 2016 Mar;30(2):103-7 [25902908.001]
  • [Cites] Mycopathologia. 2008 Nov-Dec;166(5-6):353-67 [18478357.001]
  • [Cites] J Antimicrob Chemother. 1999 Mar;43(3):411-3 [10223599.001]
  • [Cites] Indian J Dermatol. 2013 Nov;58(6):457-60 [24249898.001]
  • [Cites] J Cutan Med Surg. 2015 Sep-Oct;19(5):440-9 [25857439.001]
  • [Cites] Mycoses. 2008 Sep;51 Suppl 4:2-15 [18783559.001]
  • [Cites] J Am Acad Dermatol. 2013 Apr;68(4):600-8 [23177180.001]
  • [Cites] J Drugs Dermatol. 2015 Mar;14 (3):223-33 [25738843.001]
  • [Cites] Skin Therapy Lett. 2002;7 Suppl 1:6-7 [12432424.001]
  • [Cites] Indian J Dermatol Venereol Leprol. 2000 Jul-Aug;66(4):188-92 [20877072.001]
  • [Cites] Bioorg Med Chem. 2012 Oct 1;20(19):5678-98 [22902032.001]
  • [Cites] J Clin Aesthet Dermatol. 2014 Jul;7(7):10-8 [25053979.001]
  • [Cites] J Clin Microbiol. 2003 Oct;41(10):4817-9 [14532230.001]
  • [Cites] Indian J Dermatol. 2008;53(4):174-8 [19882028.001]
  • [Cites] Indian J Pharmacol. 2013 Nov-Dec;45(6):622-4 [24347774.001]
  • [Cites] J Clin Microbiol. 1977 Jan;5(1):34-8 [833268.001]
  • [Cites] An Bras Dermatol. 2014 Mar-Apr;89(2):259-64 [24770502.001]
  • [Cites] Int J Dermatol. 2008 Jun;47(6):584-7 [18477149.001]
  • [Cites] Int J Dermatol. 1998 Jun;37(6):450-3 [9646136.001]
  • [Cites] J Drugs Dermatol. 2014 Jan;13(1):32-8 [24385117.001]
  • [Cites] J Am Acad Dermatol. 2015 Jul;73(1):62-9 [25956661.001]
  • [Cites] Indian J Dermatol. 2015 Mar-Apr;60(2):153-8 [25814703.001]
  • (PMID = 28923039.001).
  • [ISSN] 1472-6882
  • [Journal-full-title] BMC complementary and alternative medicine
  • [ISO-abbreviation] BMC Complement Altern Med
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Infective Agents
  • [Keywords] NOTNLM ; AMYCOT® / Calmagen® / Cyanobacterium-derived anti-fungal / Natural antifungal / Onychomycosis / Superficial dermatophytosis / Tinea
  •  go-up   go-down


46. Chalmers JR, Haines RH, Mitchell EJ, Thomas KS, Brown SJ, Ridd M, Lawton S, Simpson EL, Cork MJ, Sach TH, Bradshaw LE, Montgomery AA, Boyle RJ, Williams HC: Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (The BEEP trial): protocol for a randomised controlled trial. Trials; 2017 Jul 21;18(1):343

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Atopic eczema (AE) is a common skin problem that impairs quality of life and is associated with the development of other atopic diseases including asthma, food allergy and allergic rhinitis.
  • Participating families will be randomised in a 1:1 ratio to receive general infant skin-care advice, or general skin-care advice plus emollients with advice to apply daily to the infant for the first year of life.
  • The primary outcome will be a blinded assessment of AE at 24 months of age using the UK Working Party Diagnostic Criteria for Atopic Eczema.
  • Secondary outcomes are other definitions of AE, time to AE onset, severity of AE (EASI and POEM), presence of other allergic diseases including food allergy, asthma and hay fever, allergic sensitisation, quality of life, cost-effectiveness and safety of the emollients.
  • DISCUSSION: This trial will demonstrate whether skin-barrier enhancement through daily emollient for the first year of life can prevent AE from developing in high-risk infants.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacoeconomics. 2003;21(2):105-13 [12515572.001]
  • [Cites] Br J Dermatol. 2011 Aug;165(2):329-34 [21564067.001]
  • [Cites] Br J Dermatol. 2017 Apr;176(4):979-984 [27858989.001]
  • [Cites] Nat Genet. 2009 May;41(5):602-8 [19349982.001]
  • [Cites] J Allergy Clin Immunol. 2015 Jan;135(1):164-70 [25457149.001]
  • [Cites] Health Econ. 1997 Jul-Aug;6(4):327-40 [9285227.001]
  • [Cites] J Am Acad Dermatol. 2016 Nov;75(5):1038-1044 [27522613.001]
  • [Cites] Health Econ. 2001 Dec;10(8):779-87 [11747057.001]
  • [Cites] J Allergy Clin Immunol. 2014 Oct;134(4):818-23 [25282563.001]
  • [Cites] Arch Dis Child. 2011 Mar;96(3):227-31 [21068081.001]
  • [Cites] Int J Technol Assess Health Care. 2005 Spring;21(2):240-5 [15921065.001]
  • [Cites] Allergy Asthma Immunol Res. 2011 Apr;3(2):67-73 [21461244.001]
  • [Cites] J Allergy Clin Immunol. 2014 Oct;134(4):824-830.e6 [25282564.001]
  • [Cites] Br J Dermatol. 2016 Nov;175(5):1011-1019 [27097823.001]
  • [Cites] J Allergy Clin Immunol. 2016 Apr;137(4):1071-8 [26897122.001]
  • [Cites] Pediatrics. 2004 May;113(5):1195-203 [15121929.001]
  • [Cites] J Allergy Clin Immunol. 2013 Dec;132(6):1337-47 [24035157.001]
  • [Cites] Value Health. 2015 Mar;18(2):161-72 [25773551.001]
  • [Cites] Nat Genet. 2006 Apr;38(4):441-6 [16550169.001]
  • [Cites] Clin Exp Allergy. 2015 Jan;45(1):255-64 [25210971.001]
  • [Cites] J Allergy Clin Immunol. 2012 Dec;130(6):1260-74 [23195525.001]
  • [Cites] Allergy. 2017 Mar;72 (3):453-461 [27670637.001]
  • [Cites] Nat Genet. 2007 May;39(5):650-4 [17417636.001]
  • [Cites] N Engl J Med. 2011 Oct 6;365(14):1315-27 [21991953.001]
  • [Cites] Br J Dermatol. 2010 May;162(5):1088-92 [20199550.001]
  • [Cites] Clin Exp Allergy. 2009 Dec;39(12 ):1889-95 [19817751.001]
  • [Cites] Allergy. 2017 Jan;72 (1):146-163 [27322918.001]
  • [Cites] Br J Dermatol. 1994 Sep;131(3):406-16 [7918017.001]
  • [Cites] J Allergy Clin Immunol. 2009 Dec;124(6):1251-8.e23 [20004783.001]
  • [Cites] J Allergy Clin Immunol. 2014 Oct;134(4):800-7 [25282560.001]
  • [Cites] J Allergy Clin Immunol. 2007 Sep;120(3):565-9 [17655920.001]
  • [Cites] BMC Dermatol. 2012 Jul 27;12:11 [22839963.001]
  • [Cites] J Allergy Clin Immunol. 2004 May;113(5):832-6 [15131563.001]
  • [Cites] Clin Exp Allergy. 2004 Apr;34(4):520-6 [15080802.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2009 Nov;23(11):1267-72 [19508310.001]
  • (PMID = 28732519.001).
  • [ISSN] 1745-6215
  • [Journal-full-title] Trials
  • [ISO-abbreviation] Trials
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Atopic dermatitis / Barrier enhancement / Core outcomes / Eczema / Emollient / Filaggrin / Prevention / Protocol / Randomised controlled trial
  •  go-up   go-down


47. Baselga J, Schwartzberg LS, Petrenciuc O, Shan M, Gradishar WJ: Design of RESILIENCE: A phase (Ph) III trial comparing capecitabine (CAP) in combination with sorafenib (SOR) or placebo (PL) for treatment (tx) of locally advanced (adv) or metastatic HER2-negative breast cancer (BC). J Clin Oncol; 2011 May 20;29(15_suppl):TPS124

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most drug-related adverse events were grade 1/2 in severity with the exception of grade 3 hand-foot skin reaction/syndrome (HFSR/HFS) (44% in SOR+CAP vs 14% in PL+CAP).
  • Radiographic assessment is every 6 wk for the first 36 wk, and every 9 wk thereafter.
  • Secondary endpoints include overall survival, time to progression, overall response rate, duration of response (RECIST 1.1 criteria), and safety.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28022937.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Shen Y, Hsu C, Hsu C, Lin Z, Chen P, Shao Y, Huang T, Ding Y, Cheng A: A phase II study of sorafenib in combination with tegafur/uracil (UFT) for Asian patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol; 2009 May 20;27(15_suppl):4589

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We conducted a phase II study to evaluate the efficacy and safety of sorafenib plus low-dose UFT in advanced HCC patients (pts).
  • Tumor assessment was performed q8w by RECIST criteria.
  • Hand-foot skin reaction (HFSR), fatigue, and diarrhea were most common AEs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963091.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Heinemann V, Fischer von Weikersthal L, Vehling-Kaiser U, Stauch M, Hass H, Dietzfelbinger HF, Oruzio DV, Klein S, Zellmann K, Decker T, Schulze M, Abenhardt W, Puchtler G, Kappauf HW, Mittermueller J, Haberl C, Giessen CA, Moosmann N, Stintzing S: Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer (mCRC): AIO KRK-0104 trial. J Clin Oncol; 2011 May 20;29(15_suppl):3589

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer (mCRC): AIO KRK-0104 trial.
  • : 3589 Background: The AIO KRK-0104 randomized phase II trial investigated the efficacy and safety of two capecitabine-based regimens: CAPIRI plus cetuximab (CAPIRI-C) and CAPOX plus cetuximab (CAPOX-C) in the first-line treatment of metastatic colorectal cancer (mCRC).
  • Treatment related skin toxicity was evaluated separately for capecitabine and cetuximab.
  • The present analysis investigates the correlation of capecitabine-attributed skin toxicity (Cape-ST) and parameters of treatment efficacy.
  • RESULTS: Of 185 recruited patients, 149 patients (CAPIRI-C, n=78; CAPOX-C, n=71) received study treatment beyond the first tumor assessment and were evaluable for efficacy.
  • While cetuximab-specific skin toxicity such as acneiform rash, dry skin and others occurred in >90% of patients, Cape-ST, predominantly hand-foot syndrome, was observed in only 33.2% of patients.
  • CONCLUSIONS: This analysis supports the hypothesis that for the evaluated regimens a correlation exists between capecitabine-specific skin toxicity and treatment efficacy regarding DCR, PFS and OS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28020253.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Hojerová J, Peráčková Z, Beránková M: Margin of safety for two UV filters estimated by in vitro permeation studies mimicking consumer habits: Effects of skin shaving and sunscreen reapplication. Food Chem Toxicol; 2017 May;103:66-78
Hazardous Substances Data Bank. 2-HYDROXY-4-METHOXYBENZOPHENONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Margin of safety for two UV filters estimated by in vitro permeation studies mimicking consumer habits: Effects of skin shaving and sunscreen reapplication.
  • Sunscreens are intended to work on the skin.
  • The potential for systemic absorption of Benzophenone-3 (BP3, 10%) and Ethylhexyl Triazone (EHT, 5%) in a silicone-based water-in-oil emulsion was assessed in vitro using a full-thickness porcine-ear skin mimicking in-use conditions.
  • (ii) on the whole-body skin, was (i) 136 and 30;.
  • Skin shaving increased BP3 and EHT bioavailability 1.38 and 1.80-fold, respectively.
  • Margin of Safety values were estimated according to guidelines applicable for European Union.
  • For three realistic exposure scenarios, MoS of 48, 34 and 34 for BP3 in the sunscreen applied on the whole-body indicate some concerns regarding the safety for consumers (MoS<100).
  • [MeSH-major] Benzophenones / adverse effects. Drug Evaluation, Preclinical / methods. Skin / drug effects. Skin Absorption / drug effects. Sunscreening Agents / adverse effects

  • MedlinePlus Health Information. consumer health - Sun Exposure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28216167.001).
  • [ISSN] 1873-6351
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzoates; 0 / Benzophenones; 0 / Emulsions; 0 / Sunscreening Agents; 0 / Triazines; 88122-99-0 / octyl triazone; 95OOS7VE0Y / oxybenzone
  • [Keywords] NOTNLM ; Benzophenone-3 / Ethylhexyl triazone / Human exposure assessment / Margin of safety / Shaving skin / Systemic exposure dose
  •  go-up   go-down


51. Olsen DS, Lee M, Turley AP: Assessment of test method variables for in vitro skin irritation testing of medical device extracts. Toxicol In Vitro; 2017 Nov 24;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of test method variables for in vitro skin irritation testing of medical device extracts.
  • Skin irritation is an important component of the biological safety evaluation of medical devices.
  • However, in an effort to reduce the need for in vivo testing, alternative methods for assessing skin irritation potential in vitro have been developed using a Reconstructed Human Epidermis (RhE) model.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017. Published by Elsevier Ltd.
  • (PMID = 29180040.001).
  • [ISSN] 1879-3177
  • [Journal-full-title] Toxicology in vitro : an international journal published in association with BIBRA
  • [ISO-abbreviation] Toxicol In Vitro
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Alternative testing / In vitro / Irritation / Medical devices / Reconstructed human epidermis
  •  go-up   go-down


52. Rodrigues AM, Sniehotta FF, Birch-Machin MA, Araujo-Soares V: Aware, motivated and striving for a 'safe tan': an exploratory mixed-method study of sun-protection during holidays. Health Psychol Behav Med; 2017;5(1):276-298

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • <b>Methods:</b> Seventeen participants aged 21-62 years old, recruited from community settings took part in individual face-to-face semi-structured interviews, completed sun sensitivity questions and an objective assessment of sunscreen use.
  • They are aware of the need to protect from solar UVR, but the motive for a safe tan, the overreliance on sunscreen, the overestimation of the safe sun-exposure time for their skin type and the insufficient application of sunscreen leaves holidaymakers motivated to protect their skin at significant risk of overexposure, sunburn and skin cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Dermatol. 2016 Dec;175(6):1401-1403 [27292412.001]
  • [Cites] Int J Behav Nutr Phys Act. 2015 Feb 21;12:25 [25889481.001]
  • [Cites] Pediatrics. 2002 Jun;109(6):1009-14 [12042536.001]
  • [Cites] Health Psychol. 2000 Sep;19(5):469-78 [11007155.001]
  • [Cites] Health Educ Res. 2011 Feb;26(1):39-52 [21059798.001]
  • [Cites] J Skin Cancer. 2012;2012:480985 [22649734.001]
  • [Cites] Health Educ Behav. 2001 Jun;28(3):290-305 [11380050.001]
  • [Cites] Implement Sci. 2012 Apr 24;7:35 [22531601.001]
  • [Cites] Br J Cancer. 2011 Dec 6;105 Suppl 2:S66-9 [22158324.001]
  • [Cites] J Natl Cancer Inst. 1998 Dec 16;90(24):1873-80 [9862624.001]
  • [Cites] Eur J Public Health. 2006 Oct;16(5):492-7 [16195355.001]
  • [Cites] J Am Acad Dermatol. 2002 May;46(5):683-9 [12004307.001]
  • [Cites] Psychooncology. 2016 Feb;25(2):158-63 [26101815.001]
  • [Cites] Br J Dermatol. 2009 Nov;161 Suppl 3:116-23 [19775367.001]
  • [Cites] Br J Dermatol. 2009 Nov;161 Suppl 3:25-7 [19775353.001]
  • [Cites] Health Psychol. 2003 Mar;22(2):199-209 [12683740.001]
  • [Cites] Health Educ Res. 2010 Feb;25(1):162-82 [19858077.001]
  • [Cites] Arch Dermatol. 2010 Sep;146(9):979-84 [20855696.001]
  • [Cites] J Cosmet Dermatol. 2004 Apr;3(2):62-8 [17147557.001]
  • [Cites] Psychol Health. 2013;28(5):477-94 [23252669.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2015 Feb;29 Suppl 2:6-10 [25639926.001]
  • [Cites] J Behav Med. 2009 Dec;32(6):532-44 [19653089.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2011 Dec;20(12):2583-93 [22016471.001]
  • [Cites] Health Educ J. 2009 Sep;68(3):232-243 [22707763.001]
  • [Cites] Ann Behav Med. 2013 Apr;45(2):224-38 [23229160.001]
  • [Cites] BMC Public Health. 2011 Aug 31;11:679 [21884577.001]
  • [Cites] Health Educ Behav. 2003 Feb;30(1):29-43 [12564666.001]
  • [Cites] J Clin Oncol. 2011 Jan 20;29(3):257-63 [21135266.001]
  • [Cites] Health Educ Res. 2005 Oct;20(5):579-85 [15644381.001]
  • [Cites] Psychol Health. 2010 Dec;25(10):1229-45 [20204937.001]
  • [Cites] Am J Prev Med. 2004 Dec;27(5):422-66 [15556744.001]
  • [Cites] J Psychol. 1975 Sep;91(1):93-114 [28136248.001]
  • [Cites] Arch Dermatol. 2008 Nov;144(11):1449-55 [19015419.001]
  • [Cites] Qual Saf Health Care. 2005 Feb;14 (1):26-33 [15692000.001]
  • [Cites] J Behav Med. 2013 Apr;36(2):109-23 [22460361.001]
  • [Cites] J Public Health (Oxf). 2014 Mar;36(1):56-64 [23365261.001]
  • [Cites] Int J Environ Res Public Health. 2016 Jan 19;13(1):null [26797627.001]
  • [Cites] Photochem Photobiol Sci. 2013 Jan;12(1):190-6 [23023728.001]
  • [Cites] Cancer Causes Control. 2011 Jul;22(7):1067-71 [21637987.001]
  • [Cites] Health Psychol. 1988;7(4):355-86 [3049068.001]
  • [Cites] J Invest Dermatol. 2007 Jan;127(1):41-8 [17068486.001]
  • [Cites] Pigment Cell Melanoma Res. 2010 Feb;23(1):57-63 [19968819.001]
  • [Cites] Br J Health Psychol. 2013 Feb;18(1):182-217 [22989352.001]
  • [Cites] Arch Dermatol. 1988 Jun;124(6):869-71 [3377516.001]
  • [Cites] J Behav Med. 1997 Apr;20(2):207-22 [9144041.001]
  • [Cites] BMJ Open. 2013 Jun 28;3(6):null [23811173.001]
  • [Cites] Am J Health Behav. 2004 Nov-Dec;28(6):531-41 [15569587.001]
  • (PMID = 28670503.001).
  • [ISSN] 2164-2850
  • [Journal-full-title] Health psychology and behavioral medicine
  • [ISO-abbreviation] Health Psychol Behav Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Sun-safety / interview / public health / skin cancer / tanning
  •  go-up   go-down


53. Dall' Oglio F, Tedeschi A, Fusto CM, Lacarrubba F, Dinotta F, Micali G: A novel cosmetic antifungal/anti-inflammatory topical gel for the treatment of mild to moderate seborrheic dermatitis of the face: an open-label trial utilizing clinical evaluation and erythema-directed digital photography. G Ital Dermatol Venereol; 2017 Oct;152(5):436-440
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Advanced digital photography, equipped with technology able to provide a detailed evaluation of red skin components corresponding to vascular flare (erythema-directed digital photography), is a useful tool for evaluation of erythema in patients affected by inflammatory dermatoses.
  • The aim of this study was to assess the efficacy and safety of a new cosmetic topical gel containing piroctone olamine, lactoferrin, glycero-phospho-inositol, and Aloe vera for the treatment of facial seborrheic dermatitis by clinical and advanced digital photography evaluation.
  • Finally, at baseline and at the end of the study, IGA (Investigator Global Assessment) was performed using a 5-point severity scale (from 0 = worsening to 4 = excellent response).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28121079.001).
  • [ISSN] 1827-1820
  • [Journal-full-title] Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia
  • [ISO-abbreviation] G Ital Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


54. Duvic M, Ziari S, Olsen EA, Foss FM: Phase 1-2 multi-center study of intravenous Bcx-1777 in patients with refractory cutaneous T-cell lymphoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):6733

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 6733 Background: Cutaneous T-cell lymphomas (CTCL) including the leukemic variant, Sezary Syndrome (SS) are incurable extra-nodal non-Hodgkin's lymphomas caused by accumulation of skin homing T-cells.
  • Clinical response was determined each course using a weighted composite of disease assessment from baseline.
  • Safety visits were conducted weekly.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014492.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Pandite L, Burris HA, Jones S, Wilding G, Taylor C, Versola MJ, Smith DA, Stead A, Koch KM, Spector NL: A safety, tolerability, and pharmacokinetic (PK) study of GW572016 in patients with solid tumors. J Clin Oncol; 2004 Jul 15;22(14_suppl):3179

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A safety, tolerability, and pharmacokinetic (PK) study of GW572016 in patients with solid tumors.
  • This phase I monotherapy study evaluated safety, tolerability, and PK in patients with advanced solid tumors at once (QD) and twice daily (BID) dosing schedules.
  • RESULTS: 81 pts with various carcinomas were enrolled; 64 pts (39 QD, 25 BID) included in safety and disease assessment; 57 included in PK.
  • There were no clinically significant changes in the other safety evaluations.
  • The majority of AEs were grade 1 or 2 skin and/or GI toxicities, manageable with symptomatic treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014929.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Huang LL, Qiu YM, Sun LL, Li J, Pan YH, Wang YL, Yuan ZH: Dietary exposure assessment of cyadox based on tissue depletion of cyadox and its major metabolites in pigs, chickens, and carp. J Vet Pharmacol Ther; 2017 Dec 01;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary exposure assessment of cyadox based on tissue depletion of cyadox and its major metabolites in pigs, chickens, and carp.
  • The tissue kinetics of cyadox, an antibacterial agent used in food animals, and its major metabolites in pigs, chickens, and carp were investigated followed by a complete dietary exposure assessment to evaluate the food safety of cyadox.
  • The residue amount of cyadox and its major metabolites in liver, kidney, muscle, and fat (skin) tissues was determined.
  • Based on these residue depletion data and previous toxicology results, the global estimated chronic dietary exposure assessment of cyadox for general population was conducted, indicating a zero withdrawal time (WDT) may be appropriate for cyadox in food animals when used in feed for prolonged administration.
  • These results provide analytical techniques and safety standards suitable for residue monitoring of cyadox in food animals.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 John Wiley & Sons Ltd.
  • (PMID = 29194660.001).
  • [ISSN] 1365-2885
  • [Journal-full-title] Journal of veterinary pharmacology and therapeutics
  • [ISO-abbreviation] J. Vet. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; HPLC / cyadox / estimates of dietary intake / metabolites / tissue depletion / withdrawal time
  •  go-up   go-down


57. Palmieri C, Stein RC, Liu X, Hudson E, Nicholas H, Sasano H, Guestini F, Holcombe C, Barrett S, Kenny L, Reed S, Lim A, Hayward L, Howell S, Coombes RC, IRIS trial participants: IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients. Breast Cancer Res Treat; 2017 Sep;165(2):343-353
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We performed a multicentre, open label phase II trial of the addition of Irosustat to a first-line aromatase inhibitor (AI) in patients with advanced BC to evaluate the safety of the combination and to test the hypothesis that the addition of Irosustat to AI may further suppress estradiol levels and result in clinical benefit.
  • Secondary endpoints included safety, tolerability, and pharmacodynamic end points.
  • RESULTS: Twenty-seven women were recruited, four discontinued treatment without response assessment.
  • The most frequently reported grade 3/4 toxicities were dry skin (28%), nausea (13%), fatigue (13%), diarrhoea (8%), headache (7%), anorexia (7%) and lethargy (7%).
  • CONCLUSIONS: The addition of Irosustat to aromatase inhibitor therapy resulted in clinical benefit with an acceptable safety profile.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Rev. 2009 Jun;30(4):343-75 [19389994.001]
  • [Cites] Clin Cancer Res. 2016 Mar 1;22(5):1130-7 [26500237.001]
  • [Cites] N Engl J Med. 2012 Feb 9;366(6):520-9 [22149876.001]
  • [Cites] Br J Cancer. 1990 Oct;62(4):679-83 [2145964.001]
  • [Cites] Clin Cancer Res. 2012 Jun 15;18(12 ):3305-15 [22550166.001]
  • [Cites] Breast Cancer Res Treat. 2010 Apr;120(3):639-48 [20151319.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2762-70 [12782580.001]
  • [Cites] Steroids. 2016 Jan;105:50-8 [26666359.001]
  • [Cites] Breast Cancer Res Treat. 1989 Jan;13(1):61-9 [2495831.001]
  • [Cites] N Engl J Med. 2016 Nov 3;375(18):1738-1748 [27717303.001]
  • [Cites] Cancer Res. 1981 Nov;41(11 Pt 1):4720-6 [6458355.001]
  • [Cites] Breast Cancer Res Treat. 2013 Jun 25;140(1):73-82 [23797179.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2001 Oct;6(4):407-17 [12013530.001]
  • [Cites] Int J Cancer. 2000 Jan 20;89(1):39-43 [10719729.001]
  • [Cites] Breast Cancer Res Treat. 2009 May;115(2):289-96 [18521740.001]
  • [Cites] Nat Rev Clin Oncol. 2010 Feb;7(2):72-4 [20118974.001]
  • [Cites] J Steroid Biochem Mol Biol. 2000 Dec 31;75(4-5):253-8 [11282279.001]
  • [Cites] Mol Cell Endocrinol. 2014 Jan 25;382(1):695-723 [23933149.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4026-9 [10945602.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 2):1008s-1012s [16467117.001]
  • [Cites] Surgery. 2001 Dec;130(6):947-53 [11742322.001]
  • [Cites] Anticancer Res. 2011 Apr;31(4):1367-72 [21508387.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Aug;88(8):3902-12 [12915686.001]
  • [Cites] Lancet Oncol. 2013 Sep;14 (10 ):989-98 [23902874.001]
  • [Cites] Cancer Res. 1986 Oct;46(10):4933-7 [2944574.001]
  • [Cites] Trends Endocrinol Metab. 1993 Mar;4(2):69-74 [18407137.001]
  • [Cites] Br J Surg. 2014 Jul;101(8):939-48 [24687409.001]
  • [Cites] Breast Cancer Res Treat. 2012 Aug;134(3):1027-39 [22456984.001]
  • [Cites] N Engl J Med. 2015 Jul 16;373(3):209-19 [26030518.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4864-9 [10519397.001]
  • [Cites] Breast Cancer. 1999 Oct 25;6(4):298-300 [11091733.001]
  • [Cites] J Steroid Biochem Mol Biol. 2000 Jul-Aug;73(5):225-35 [11070351.001]
  • [Cites] J Clin Invest. 1972 Apr;51(4):1020-33 [5014608.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1585-92 [16533785.001]
  • [Cites] Lancet. 1978 Nov 18;2(8099):1097 [82112.001]
  • (PMID = 28612226.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Aromatase / Breast cancer / Endocrine therapy / Sulfatase
  •  go-up   go-down


58. Burnham R, Playfair L, Loh E, Roberts S, Agur A: Evaluation of the Effectiveness and Safety of Ultrasound-Guided Percutaneous Carpal Tunnel Release: A Cadaveric Study. Am J Phys Med Rehabil; 2017 Jul;96(7):457-463
MedlinePlus Health Information. consumer health - Carpal Tunnel Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the Effectiveness and Safety of Ultrasound-Guided Percutaneous Carpal Tunnel Release: A Cadaveric Study.
  • Study objectives were to evaluate the accuracy of identifying key US landmarks, safety, effectiveness, and technical difficulty of TCTR.
  • Outcome measures of interest were (1) correspondence between key landmarks (median nerve and 4 bony pillars of transverse carpal ligament) identified on US and anatomical structures exposed by dissection, (2) percentage of the transverse carpal ligament transected and location of the transection, (3) frequency of damage to adjacent structures, (4) time to complete procedure, and (5) operator assessment of technical difficulty of each TCTR procedure (0 = extremely easy, 10 = extremely difficult). RESULTS:.
  • (1) Skin markings delineating the position of US-visualized landmarks corresponded almost perfectly to anatomical dissection. (2) Nine (64.2%) of 14 specimens had complete division of the transverse carpal ligament.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28628532.001).
  • [ISSN] 1537-7385
  • [Journal-full-title] American journal of physical medicine & rehabilitation
  • [ISO-abbreviation] Am J Phys Med Rehabil
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Lv R, Sun Q: A Network Meta-Analysis of Non-Melanoma Skin Cancer (NMSC) Treatments: Efficacy and Safety Assessment. J Cell Biochem; 2017 Nov;118(11):3686-3695
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Network Meta-Analysis of Non-Melanoma Skin Cancer (NMSC) Treatments: Efficacy and Safety Assessment.
  • The mainstream treatments for non-melanoma skin cancer (NMSC) include photodynamic therapy (PDT), surgery excision (SE), cryotherapy (CT), imiquimod (IM), radiotherapy (RT), 5-fluorouracil (FU), and vehicle (VE).
  • Our network meta-analysis (NMA) was aimed at evaluating the efficacy and safety of these seven treatments and providing superior ones.
  • The SUCRA results indicated that SE was the treatment with best ranking in the entire three efficacy indexes and a relatively high safety.
  • Taking efficacy and safety into account, our study recommended SE as the optimal regimen for NMSC with high efficacy considering CLR, CLC, and CRP and moderate AEs when compared with other interventions. J. Cell. Biochem.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 Wiley Periodicals, Inc.
  • (PMID = 28370183.001).
  • [ISSN] 1097-4644
  • [Journal-full-title] Journal of cellular biochemistry
  • [ISO-abbreviation] J. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; EFFICACY; SAFETY / NETWORK META-ANALYSIS / NON-MELANOMA SKIN CANCER TREATMENTS
  •  go-up   go-down


60. Murchie P, Amalraj Raja E, Brewster DH, Iversen L, Lee AJ: Is initial excision of cutaneous melanoma by General Practitioners (GPs) dangerous? Comparing patient outcomes following excision of melanoma by GPs or in hospital using national datasets and meta-analysis. Eur J Cancer; 2017 Nov;86:373-384

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • European guidelines make no recommendations, and the United Kingdom (UK) melanoma guidelines require all suspicious skin lesions to be initially treated in secondary care based on an expert consensus, which lacks supporting evidence, that primary care excision represents substandard care.
  • [MeSH-major] General Practitioners. Hospitalization. Melanoma / surgery. Primary Health Care. Skin Neoplasms / surgery. Surgeons
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Databases, Factual. Female. Humans. Ireland / epidemiology. Male. Middle Aged. Odds Ratio. Patient Safety. Proportional Hazards Models. Registries. Risk Assessment. Risk Factors. Scotland / epidemiology. Specialization. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 29100192.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Meta-Analysis
  • [Publication-country] England
  • [Keywords] NOTNLM ; Cancer / Cancer registries / Melanoma / Primary healthcare / Surgery
  •  go-up   go-down


61. Verner I, Kutscher TD: Clinical evaluation of the efficacy and safety of combined bipolar radiofrequency and optical energies vs. optical energy alone for the treatment of aging hands. Lasers Med Sci; 2017 Aug;32(6):1387-1392

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical evaluation of the efficacy and safety of combined bipolar radiofrequency and optical energies vs. optical energy alone for the treatment of aging hands.
  • This study evaluated the efficacy and safety of a novel technology, which combines bipolar radio frequency (RF) and optical energies for the cosmetic treatment of aging hands.
  • The objective of the study was to assess the efficacy, safety, tolerability, and patient satisfaction of combined bipolar radiofrequency and optical energies vs. optical energy alone for the treatment of aging hands.
  • Standardized clinical photographs were taken, and patient and investigator improvement assessment (Global Esthetic Improvement (GAI) scale), patient satisfaction, and tolerability were evaluated.
  • At the 1 and 3 months follow-up, skin laxity and pigmentation, investigator and patient improvement assessments, and satisfaction were significantly better in the hand treated with combined bipolar RF and IPL.
  • This study demonstrates the safety and efficacy of combining RF and optical energies for the esthetic improvement of aging hands.
  • Combined RF and IPL treatment was more efficient than IPL alone in improving skin pigmentation, skin laxity, and texture.
  • [MeSH-major] Hand / radiation effects. Optical Phenomena. Phototherapy / methods. Radio Waves / adverse effects. Skin Aging / radiation effects
  • [MeSH-minor] Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Patient Satisfaction. Skin Pigmentation / radiation effects. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lasers Surg Med. 2003;32(2):120-8 [12561045.001]
  • [Cites] G Ital Dermatol Venereol. 2009 Jun;144(3):229-41 [19528905.001]
  • [Cites] J Drugs Dermatol. 2005 Mar-Apr;4(2):181-6 [15776775.001]
  • [Cites] Dermatol Surg. 2005 Sep;31(9 Pt 2):1211-7; discussion 1217 [16176773.001]
  • [Cites] J Cosmet Laser Ther. 2012 Oct;14(5):208-11 [23016529.001]
  • [Cites] J Clin Aesthet Dermatol. 2010 Dec;3(12):22-30 [21203352.001]
  • [Cites] Ann Plast Surg. 2010 May;64(5):526-9 [20354432.001]
  • [Cites] J Cosmet Laser Ther. 2012 Aug;14(4):179-83 [22658062.001]
  • [Cites] Dermatol Surg. 2000 Sep;26(9):835-42; discussion 843 [10971556.001]
  • [Cites] J Am Acad Dermatol. 2008 May;58(5):719-37; quiz 738-40 [18423256.001]
  • [Cites] Semin Cutan Med Surg. 2002 Dec;21(4):238-50 [12512647.001]
  • [Cites] Dermatol Clin. 2009 Oct;27(4):491-9, vii [19850198.001]
  • [Cites] Aesthetic Plast Surg. 2009 May;33(3):283-94 [19437070.001]
  • [Cites] J Cosmet Laser Ther. 2005 Mar;7(1):11-5 [16020210.001]
  • [Cites] J Drugs Dermatol. 2006 Sep;5(8):731-8 [16989187.001]
  • [Cites] Lasers Surg Med. 2009 Sep;41(7):473-8 [19708063.001]
  • [Cites] J Drugs Dermatol. 2009 Nov;8(11 Suppl):s9-13 [19916261.001]
  • [Cites] Dermatol Surg. 2002 Dec;28(12):1115-9 [12472489.001]
  • [Cites] Dermatol Surg. 2012 Nov;38(11):1765-76 [22913399.001]
  • [Cites] J Cutan Laser Ther. 2000 Jun;2(2):59-61 [11360318.001]
  • [Cites] Semin Cutan Med Surg. 2003 Jun;22(2):115-23 [12877230.001]
  • [Cites] J Cosmet Dermatol. 2002 Oct;1(3):142-3 [17147714.001]
  • [Cites] Dermatol Surg. 2001 Jul;27(7):627-31; discussion 632 [11442612.001]
  • [Cites] Lasers Surg Med. 2005 Sep;37(3):179-85 [16175631.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2006 Oct;20(9):1070-5 [16987260.001]
  • (PMID = 28643046.001).
  • [ISSN] 1435-604X
  • [Journal-full-title] Lasers in medical science
  • [ISO-abbreviation] Lasers Med Sci
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Bipolar radiofrequency / Intense pulsed light / Laser / Noninvasive skin rejuvenation / Photo-damage / Pigmentary disorders
  •  go-up   go-down


62. Bora NS, Pathak MP, Mandal S, Mazumder B, Policegoudra R, Raju PS, Chattopadhyay P: Safety assessment and toxicological profiling of a novel combinational sunprotective dermal formulation containing melatonin and pumpkin seed oil. Regul Toxicol Pharmacol; 2017 Oct;89:1-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety assessment and toxicological profiling of a novel combinational sunprotective dermal formulation containing melatonin and pumpkin seed oil.
  • Ultraviolet (UV) radiation exposure has been known to cause irreparable damages to human skin.
  • The present work deals with the preclinical safety evaluation of the sunscreen formulation comprising of four US FDA approved UV filters; namely avobenzone, octinoxate, oxybenzone, titanium dioxide along with melatonin and pumpkin seed oil, via OECD protocols of assessing acute oral and dermal toxicity; skin sensitizing; skin irritating; ocular irritating and genotoxic potential.
  • The sunscreen formulation was found to be non-sensitizing to the skin of guinea pigs and non-irritating to both skin and eyes of rabbits.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Inc. All rights reserved.
  • (PMID = 28694170.001).
  • [ISSN] 1096-0295
  • [Journal-full-title] Regulatory toxicology and pharmacology : RTP
  • [ISO-abbreviation] Regul. Toxicol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Ames test / Dermal / Mammalian bone marrow chromosomal aberration / Mammalian erythrocyte micronucleus test / Preclinical / Safety / Sunscreen / Toxicological profiling / UV radiation protection
  •  go-up   go-down


63. Jankowska A, Czerczak S, Kupczewska-Dobecka M: [Assessment of predictive dermal exposure to chemicals in the work environment]. Med Pr; 2017 Jun 27;68(4):557-569
MedlinePlus Health Information. consumer health - Occupational Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Assessment of predictive dermal exposure to chemicals in the work environment].
  • Assessment of dermal exposure to chemicals in the work environment is problematic, mainly as a result of the lack of measurement data on occupational exposure to chemicals.
  • Due to common prevalence of occupational skin exposure and its health consequences it is necessary to look for efficient solutions allowing for reliable exposure assessment.
  • This paper presents examples of models to assist the employer in the the assessment of occupational exposure associated with the skin contact with chemicals, developed in European Union (EU) countries, as well as in countries outside the EU.
  • Based on the literature data dermal exposure models EASE (Estimation and Assessment of Substance Exposure), COSHH Essentials (Control of Substances Hazardous to Health Regulations), DREAM (Dermal Exposure Assessment Method), Stoffenmanager , ECETOC TRA (European Centre for Ecotoxicology and Toxicology of Chemicals Targeted Risk Assessment), MEASE (Metal's EASE), PHED (Pesticide Handlers Exposure Database), DERM (Dermal Exposure Ranking Method) and RISKOFDERM (Risk Assessment of Occupational Dermal Exposure to Chemicals) were briefly described.
  • Problem of full work shift dermal exposure assessment is described.
  • An example of exposure assessment using RISKOFDERM and effectiveness evaluation to date were also presented.
  • When no measurements are available, RISKOFDERM allows dermal exposure assessment and thus can improve the risk assessment quality and effectiveness of dermal risk management.
  • Na podstawie danych literaturowych w artykule krótko opisano wybrane modele do szacowania narażenia dermalnego: EASE (Estimation and Assessment of Substance Exposure – oszacowanie i ocena narażenia na substancję), COSHH Essentials (Control of Substances Hazardous to Health Regulations – utrzymywanie pod kontrolą substancji niebezpiecznych dla zdrowia), DREAM (Dermal Exposure Assessment Method – metoda oceny narażenia dermalnego), Stoffenmanager, ECETOC TRA (European Centre for Ecotoxicology and Toxicology of Chemicals Targeted Risk Assessment – ukierunkowane szacowanie ryzyka Europejskiego Centrum ds.
  • Ekotoksykologii i Toksykologii Chemikaliów), MEASE (Metal’s EASE), PHED (Pesticide Handlers Exposure Database – baza danych na temat narażenia użytkowników pestycydów), DERM (Dermal Exposure Ranking Method – metoda rankingu narażenia dermalnego) i RISKOFDERM (Risk Assessment of Occupational Dermal Exposure to Chemicals – ocena ryzyka wynikającego z narażenia dermalnego na chemikalia).
  • [MeSH-major] Environmental Monitoring / methods. Occupational Exposure / analysis. Risk Assessment / methods. Skin

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] This work is available in Open Access model and licensed under a CC BY-NC 3.0 PL license.
  • (PMID = 28638154.001).
  • [ISSN] 0465-5893
  • [Journal-full-title] Medycyna pracy
  • [ISO-abbreviation] Med Pr
  • [Language] pol
  • [Publication-type] Journal Article; Review
  • [Publication-country] Poland
  • [Keywords] NOTNLM ; RISKOFDERM / dermal exposure / exposure assessment / occupational exposure / occupational hygiene / predictive models
  •  go-up   go-down


64. Jones K, Johnson PD, Baldwin PEJ, Coldwell M, Cooke J, Keen C, Harding AH, Smith D, Cocker J: Exposure to Diisocyanates and Their Corresponding Diamines in Seven Different Workplaces. Ann Work Expo Health; 2017 Apr 01;61(3):383-393

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because of this, any exposure to the diamines themselves released during the industrial process could confound the assessment of diisocyanate exposure.
  • This paper reports an initial assessment of the extent of diamine formation and exposure during different processes involving diisocyanates including casting, grouting, core making, spray painting, foam blowing, and floor screeding.
  • Some non-aerosol processes gave rise to substantial diamine levels in urine (in exceedance of international guidance values, >5 µmol mol-1 creatinine) despite airborne levels being well within occupational exposure limits (20 µg m-3 total NCO in Great Britain); measurement data and statistical modelling indicated that skin absorption was the most likely exposure route.
  • It also demonstrates the potential for substantial skin absorption of diisocyanates in certain processes such as floor screeding and foam production.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Crown Copyright 2017.
  • (PMID = 28355438.001).
  • [ISSN] 2398-7316
  • [Journal-full-title] Annals of work exposures and health
  • [ISO-abbreviation] Ann Work Expo Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; NCO / diamines / diisocyanates / floor screeding / foam blowing / skin absorption
  •  go-up   go-down


65. Crawford J, Sandler AB, Hammond LA, Schiller J, Belani C, Kozloff M, Johnson D, Fleishman A, Lee S, Takeshita K: ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2004 Jul 15;22(14_suppl):7083

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is a report of results from part 1 of a 2-part, phase 2 trial to evaluate the efficacy, safety, and pharmacokinetics (PK) of ABX-EGF in combination with paclitaxel and carboplatin for advanced NSCLC.
  • One pt (5%) had a confirmed complete response (1.0 mg/kg) and 4 pts (21%) had partial responses (2 at 2.0 mg/kg and 2 at 2.5 mg/kg) by investigator assessment.
  • The most common adverse event (AE) was skin rash (89% overall; 83%, 100%, and 83% in the 1.0, 2.0, and 2.5 mg/kg groups).
  • The incidence of grade 3 skin rash did not appear to increase with dose (17% at 1.0 mg/kg, 29% at 2.0 mg/kg, and 0% at 2.5 mg/kg).
  • Four pts (1 at 1.0 mg/kg and 3 at 2.0 mg/kg) had ABX-EGF dosing interrupted or reduced because of skin toxicities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016137.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Mason JM, Chalmers JR, Godec T, Nunn AJ, Kirtschig G, Wojnarowska F, Childs M, Whitham D, Schmidt E, Harman K, Walton S, Chapman A, Williams HC, UK Dermatology Clinical Trials Network BLISTER Study Group: Doxycycline compared to prednisolone therapy for patients with bullous pemphigoid: cost-effectiveness analysis of the BLISTER trial. Br J Dermatol; 2017 Sep 22;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Bullous pemphigoid (BP) is an autoimmune blistering skin disorder associated with significant morbidity and mortality.
  • Within-trial analysis used bivariate regression of costs and QALYs, with multiple imputation of missing data, informing a probabilistic assessment of incremental treatment cost-effectiveness from a health service perspective RESULTS: In the base case, there was no robust difference in costs or QALYs per patient at 1 year comparing doxycycline-initiated therapy with prednisolone-initiated therapy (net cost: £959, 95% CI -£24 to £1941; net QALYs: -0.024, 95% CI -0.088 to 0.041).
  • CONCLUSIONS: Consistent with the clinical findings of the BLISTER trial, patients with mild or moderate blistering should receive treatment guided by the safety and effectiveness of the drugs and patient preference - neither strategy is clearly a preferred use of NHS resources.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] This article is protected by copyright. All rights reserved.
  • (PMID = 28940316.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


67. Hecht JR, Patnaik A, Malik I, Venook A, Berlin J, Croghan G, Wiens BL, Visonneau S, Jerian S, Meropol NJ: ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): An updated analysis. J Clin Oncol; 2004 Jul 15;22(14_suppl):3511

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: This phase 2 study assessed the efficacy and safety of ABX-EGF monotherapy in pts with mCRC who previously failed therapy with a fluoropyrimidine and irinotecan or oxaliplatin or both.
  • Of 148 pts with evaluations after 8 weeks, 15 (10.1%; 95%CI: 5.8%, 16.2%) had confirmed partial responses (12 cohort A, 3 cohort B) and 54 (36.5%) had stable disease (39 cohort A, 15 cohort B) by investigator assessment.
  • The most frequent adverse event (AE) was skin rash (> 90%) [3.4% grade 3].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016465.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Cheng CY, Huang YL, Lee MC, Chang SL, Lin YF, Hu S: Pulsed alexandrite laser for treatment of melasma in Asian patients. J Cosmet Laser Ther; 2017 Aug;19(4):210-214

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present study was conducted to evaluate the efficacy and safety of pulsed alexandrite laser for the treatment of melasma.
  • The severity of melasma was evaluated by a blinded dermatologist, using the Modified Melasma Area and Severity Index (MMASI), and by patient assessment, using a visual analogue scale, at baseline, before each treatment, and at the 1-month and 3-month follow-up visits after the last treatment.
  • The treatments were well tolerated with only mild skin reaction.
  • CONCLUSION: In the present study, we demonstrated that the pulsed alexandrite laser is safe and effective to treat melasma in Asian skin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28151024.001).
  • [ISSN] 1476-4180
  • [Journal-full-title] Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology
  • [ISO-abbreviation] J Cosmet Laser Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Alexandrite laser / Asian / melasma
  •  go-up   go-down


69. Avonto C, Wang M, Chittiboyina AG, Vukmanovic S, Khan IA: Chemical stability and in chemico reactivity of 24 fragrance ingredients of concern for skin sensitization risk assessment. Toxicol In Vitro; 2018 Feb;46:237-245

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemical stability and in chemico reactivity of 24 fragrance ingredients of concern for skin sensitization risk assessment.
  • Twenty-four pure fragrance ingredients have been identified as potential concern for skin sensitization.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28927722.001).
  • [ISSN] 1879-3177
  • [Journal-full-title] Toxicology in vitro : an international journal published in association with BIBRA
  • [ISO-abbreviation] Toxicol In Vitro
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; DCYA / Fragrance ingredients / In chemico methods / Skin sensitization / Stability studies
  •  go-up   go-down


70. Cohn AL, Smith DA, Neubauer MA, Houston G, Khandelwal P, Wiggans RG, Zhang K, Yassine M: Results from panitumumab (pmab) regimen evaluation in colorectal cancer to estimate primary response to treatment (PRECEPT): Second-line treatment with pmab and FOLFIRI by tumor KRAS status. J Clin Oncol; 2009 May 20;27(15_suppl):4067

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Efficacy (objective response, progression-free survival [PFS], and overall survival [OS]) and safety were evaluated by KRAS status.
  • RESULTS: In an interim analysis (May 2008) of 115 pts who had received ≥ 1 dose of pmab, 109 pts had known KRAS status (59% had tumors with wild-type [WT] KRAS, 41% had mutant [MT] KRAS tumors), and 102 pts had the opportunity to have their first tumor assessment.
  • Most common AEs were skin-related toxicities (86% of pts), diarrhea (72%), and nausea (53%); there was no evidence that incidence of AEs was related to KRAS status.
  • Pmab had a safety profile consistent with other FOLFIRI + pmab trials.
  • Final efficacy and safety data will be presented.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961606.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Burnett CL, Heldreth B, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, Andersen FA: Safety Assessment of Amino Acid Alkyl Amides as Used in Cosmetics. Int J Toxicol; 2017 May/Jun;36(1_suppl):17S-56S

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety Assessment of Amino Acid Alkyl Amides as Used in Cosmetics.
  • The Cosmetic Ingredient Review Expert Panel (Panel) reviewed the product use, formulation, and safety data of 115 amino acid alkyl amides, which function as skin and hair conditioning agents and as surfactants-cleansing agents in personal care products.
  • Safety test data on dermal irritation and sensitization for the ingredients with the highest use concentrations, lauroyl lysine and sodium lauroyl glutamate, were reviewed and determined to adequately support the safe use of the ingredients in this report.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28553738.001).
  • [ISSN] 1092-874X
  • [Journal-full-title] International journal of toxicology
  • [ISO-abbreviation] Int. J. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; amino acid alkyl amides / cosmetics / safety
  •  go-up   go-down


72. Frederick DM, Vorwerk L, Gupta A, Ghassemi A: Dermal safety assessment of Arm & Hammer laundry products formulated for sensitive skin. Cutan Ocul Toxicol; 2017 Sep;36(3):263-272

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermal safety assessment of Arm & Hammer laundry products formulated for sensitive skin.
  • CONTEXT: The prevalence of sensitive skin among the general population in industrialized countries is reported to be over 50%.
  • Sensitive skin subjects often report significant reactions to contact with cosmetics, soaps and other consumer products.
  • OBJECTIVE: This paper describes the overall skin compatibility and mildness program for a newly developed, lightly fragranced, colorant free laundry product (i.e.
  • Arm & Hammer™ Sensitive Skin plus Skin-Friendly Fresh Scent), specially formulated for individuals with sensitive skin.
  • The skin mildness of the product was compared to Arm & Hammer™ Free & Clear liquid laundry detergent with no fragrance or colorant, and an established history of safe use by sensitive skin consumers.
  • MATERIALS AND METHODS: The test material was a liquid laundry product with a light scent formulated for sensitive skin consumers (Arm & Hammer™ Sensitive Skin plus Skin-Friendly Fresh Scent).
  • The product was compared to commercially marketed products for sensitive skin with a history of skin safety in the marketplace, including: a very similar product formulation (Arm & Hammer™ Free & Clear with no fragrance), and several selected competitors' products.
  • Studies were conducted among individuals with self-assessed sensitive skin (based on a questionnaire) using standard protocols for the Human Repeat Insult Patch Test (HRIPT), 10-Day Cumulative Irritation, the Wrist Band Wear test, and the Safety In-Use testing.
  • RESULTS: The HRIPT confirmed that neither the fragrance alone, nor the product formulation with fragrance, induced contact sensitization in sensitive skin subjects.
  • The 10-Day cumulative irritation study conducted using sensitive skin subjects showed highly favorable skin compatibility, and the test product was comparable to the control product (Arm & Hammer Free & Clear) and other nonirritant controls.
  • In the Wrist Band Wear test, exposure to laundered fabrics under exaggerated conditions gave similar results for the test and control products, with no objective signs of skin irritation, and no self-reported persistent adverse sensory effects.
  • The Safety In-Use tests evaluated 4-week exposure to product and laundered fabrics under realistic use conditions.
  • There were no clinically objective signs of skin irritation, and reports of transitory, mild sensory effects were minimal and similar for the test and controls.
  • DISCUSSION AND CONCLUSION: A comprehensive skin safety program on a lightly scented sensitive skin laundry formulation (i.e.
  • Arm & Hammer™ Sensitive Skin plus Skin-Friendly Fresh Scent) conducted among panels of self-assessed sensitive skin subjects demonstrated that the presence of a light fragrance did not adversely impact skin compatibility in any of the testing protocols when the product was compared to a similar product with no fragrance.
  • The lightly fragranced product demonstrated overall skin compatibility and mildness when tested in a self-assessed sensitive skin population, and compared favorably to currently marketed sensitive skin products.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28073339.001).
  • [ISSN] 1556-9535
  • [Journal-full-title] Cutaneous and ocular toxicology
  • [ISO-abbreviation] Cutan Ocul Toxicol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Consumer product safety / contact sensitization / cumulative irritation / safety in use test / sensitive skin / skin irritation / wrist band test
  •  go-up   go-down


73. Cunningham G, Belkoff L, Brock G, Efros M, Gittelman M, Carrara D, Neijber A, Ando M, Mitchel J: EFFICACY AND SAFETY OF A NEW TOPICAL TESTOSTERONE REPLACEMENT GEL THERAPY FOR THE TREATMENT OF MALE HYPOGONADISM. Endocr Pract; 2017 May;23(5):557-565
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EFFICACY AND SAFETY OF A NEW TOPICAL TESTOSTERONE REPLACEMENT GEL THERAPY FOR THE TREATMENT OF MALE HYPOGONADISM.
  • This study aimed to evaluate the efficacy and safety of testosterone gel 2% (Tgel) over 90 days.
  • Safety endpoints were adverse events (AEs), laboratory parameters, and vital signs.
  • Tgel had a favorable local skin tolerability profile.
  • Symptoms of testosterone deficiency improved with few safety concerns.
  • ABBREVIATIONS: AE = adverse event C<sub>ave(0-24)</sub> = average testosterone concentration CI = confidence interval C<sub>max</sub> = maximum concentration IIEF = International Index of Erectile Function MAF = Multidimensional Assessment of Fatigue PK = pharmacokinetic PSA = prostate-specific antigen SAE = serious adverse event SF-12 = Short Form 12 Health Survey Tgel = testosterone gel 2% T<sub>max</sub> = time to achieve maximum concentration TRT = testosterone replacement therapy.

  • MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28225313.001).
  • [ISSN] 1530-891X
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gels; 3XMK78S47O / Testosterone
  •  go-up   go-down


74. Adjadj L, SidAhmed-Mezi M, Mondoloni M, Meningaud JP, Hersant B: Assessment of the Efficacy of Cryolipolysis on Saddlebags: A Prospective Study of 53 Patients. Plast Reconstr Surg; 2017 Jul;140(1):50-57

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of the Efficacy of Cryolipolysis on Saddlebags: A Prospective Study of 53 Patients.
  • The main objective of this study was to demonstrate the efficacy, patient tolerance, and safety of cryolipolysis on the saddlebags.
  • Reversible skin changes such as postprocedure postinflammatory hyperpigmentation were observed in 8.33 percent of patients.
  • A substantial risk of skin lesions, including postinflammatory hyperpigmentation that resolved after a few months, was observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Plast Reconstr Surg. 2017 Jul;140(1):58-59 [28654589.001]
  • (PMID = 28654588.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Makino ET, Kadoya K, Sigler ML, Hino PD, Mehta RC: Development and Clinical Assessment of a Comprehensive Product for Pigmentation Control in Multiple Ethnic Populations. J Drugs Dermatol; 2016 Dec 01;15(12):1562-1570
Hazardous Substances Data Bank. HYDROQUINONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development and Clinical Assessment of a Comprehensive Product for Pigmentation Control in Multiple Ethnic Populations.
  • OBJECTIVES: To develop a comprehensive product (LYT2) that affects all major biological pathways controlling pigmentation and test for clinical efficacy and safety in different ethnic populations.
  • METHODS: A thorough analysis of biological pathways was used to identify ingredient combinations for LYT2 that provided optimal melanin reduction in a 3-D skin model.
  • The outcome clearly shows greater pigmentation control with LYT2 compared to other HQ-free products in skin tissue models and earlier control in clinical studies compared to 4% HQ.
  • [MeSH-major] Ethnic Groups. Hydroquinones / administration & dosage. Melanins / antagonists & inhibitors. Skin Lightening Preparations / administration & dosage. Skin Pigmentation / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28095579.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hydroquinones; 0 / Melanins; 0 / Skin Lightening Preparations; XV74C1N1AE / hydroquinone
  •  go-up   go-down


76. Chu CH, Davis C: Urticarial Reaction to Ustekinumab During the Treatment of Plaque Psoriasis in a Hepatitis C-Positive Patient. Drug Saf Case Rep; 2017 Dec;4(1):9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After 10 months, she developed a round red rash on her skin diffusely on her body.
  • A Naranjo assessment score of 6 was obtained, indicating a probable relationship between the patient's urticaria and her use of ustekinumab.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2008 May 17;371(9625):1675-84 [18486740.001]
  • [Cites] Ann Dermatol. 2016 Apr;28(2):222-31 [27081271.001]
  • [Cites] Dermatol Reports. 2013 Sep 09;5(1):e2 [25386321.001]
  • [Cites] Int J Dermatol. 1996 Nov;35(11):797-9 [8915733.001]
  • [Cites] Acta Derm Venereol. 1995 Nov;75(6):482-3 [8651030.001]
  • [Cites] J Am Acad Dermatol. 2011 Jul;65(1):137-74 [21306785.001]
  • [Cites] J Invest Dermatol. 2013 Feb;133(2):377-85 [23014338.001]
  • [Cites] J Rheumatol. 1996 Jun;23(6):979-83 [8782126.001]
  • [Cites] J Am Acad Dermatol. 1998 Oct;39(4 Pt 2):S129-33 [9777790.001]
  • [Cites] J Am Acad Dermatol. 2014 Mar;70(3):512-6 [24388724.001]
  • [Cites] J Am Acad Dermatol. 1996 Aug;35(2 Pt 1):195-8 [8708019.001]
  • [Cites] Lancet. 2008 May 17;371(9625):1665-74 [18486739.001]
  • [Cites] J Rheumatol. 1999 Feb;26(2):370-2 [9972971.001]
  • (PMID = 28677075.001).
  • [ISSN] 2199-1162
  • [Journal-full-title] Drug safety - case reports
  • [ISO-abbreviation] Drug Saf Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


77. van Vliet E, Kühnl J, Goebel C, Martinozzi-Teissier S, Alépée N, Ashikaga T, Blömeke B, Del Bufalo A, Cluzel M, Corsini E, Delrue N, Desprez B, Gellatly N, Giese C, Gribaldo L, Hoffmann S, Klaric M, Maillere B, Naisbitt D, Pallardy M, Vocanson M, Petersohn D: State-of-the-art and new options to assess T cell activation by skin sensitizers: Cosmetics Europe Workshop. ALTEX; 2017 Oct 02;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] State-of-the-art and new options to assess T cell activation by skin sensitizers: Cosmetics Europe Workshop.
  • Significant progress has been made in the development and validation of non-animal test methods for skin sensitization assessment.
  • The Cosmetics Europe Skin Tolerance Task Force organized a workshop, bringing together academic researchers, method developers, industry representatives and regulatory stakeholders to review the scientific status of T cell-based assays, foster a mutual scientific understanding and conceive new options to assess T cell activation.
  • Furthermore, the potential role of T cell assays in AOP-based testing strategies and subsequent safety assessment concepts for cosmetic ingredients was discussed.
  • It was agreed that it is currently difficult to anticipate uses of T cell assay data for safety assessment and concluded that experience from case studies on real-life risk assessment scenarios is needed to further consider the usefulness of assessing the fourth AOP key event.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28968481.001).
  • [ISSN] 1868-596X
  • [Journal-full-title] ALTEX
  • [ISO-abbreviation] ALTEX
  • [Language] eng
  • [Publication-type] Consensus Development Conference
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; adverse outcome pathway / T cell assays / key events / safety assessment / skin sensitization
  •  go-up   go-down


78. Wang S, Mi J, Li Q, Jin R, Dong J: Fractional microplasma radiofrequency technology for non-hypertrophic post-burn scars in Asians: A prospective study of 95 patients. Lasers Surg Med; 2017 Aug;49(6):563-569

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the various techniques, fractional microplasma radiofrequency technology (FMRT) has proven to be an effective treatment option for various types of scars and skin conditions such as rhytids, striae distensae, and hyperpigmentation.
  • OBJECTIVE: This prospective clinical trial was designed to evaluate the efficacy and safety of FMRT for treating non-hypertrophic post-burn scars in the Asian population.
  • The Patient and Observer Scar Assessment Scales (POSAS) [20] were used to evaluate changes in burn scars pre-and post-FMRT treatment.
  • No severe adverse events, such as acute skin infection, hypertrophic scarring, or depigmentation, were observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 Wiley Periodicals, Inc.
  • (PMID = 28220505.001).
  • [ISSN] 1096-9101
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; burns / cicatrix / lasers / micro-plasma / radiofrequency / scars
  •  go-up   go-down


79. Pullman J, Gardovskis J, Farley B, Sun E, Quintas M, Lawrence L, Ling R, Cammarata S, PROCEED Study Group: Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study. J Antimicrob Chemother; 2017 Dec 01;72(12):3471-3480

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study.
  • Objectives: To establish the non-inferiority of delafloxacin compared with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections and to compare the safety of the two antimicrobials.
  • Non-inferiority was evaluated by objective response (≥20% erythema reduction) at 48-72 h after initiation of study drug, investigator subjective assessment of outcome and microbiological responses.
  • Conclusions: Delafloxacin, an anionic fluoroquinolone, was statistically non-inferior to vancomycin/aztreonam at 48-72 h following the start of therapy and was well tolerated as monotherapy in the treatment of acute bacterial skin and skin structure infections.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 29029278.001).
  • [ISSN] 1460-2091
  • [Journal-full-title] The Journal of antimicrobial chemotherapy
  • [ISO-abbreviation] J. Antimicrob. Chemother.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


80. Helmer E, Watling M, Jones E, Tytgat D, Jones M, Allen R, Payne A, Koch A, Healy E: First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases. Eur J Clin Pharmacol; 2017 May;73(5):581-591
MedlinePlus Health Information. consumer health - Psoriasis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These studies aimed to investigate the safety, tolerability and PK profile of seletalisib, a selective inhibitor of PI3Kδ in humans.
  • Pharmacodynamic effects on markers of inflammation were assessed via changes in ex vivo basophil degranulation and histological assessment of psoriatic skin biopsies.
  • No safety concerns or dose-limiting toxicities were identified (Study-1).
  • Pharmacodynamic findings demonstrated ex vivo inhibition of basophil degranulation, improvements in histological assessment of skin biopsies and other markers of psoriatic biology and preliminary evidence of target engagement in psoriatic skin tissue.
  • CONCLUSIONS: Seletalisib safety, tolerability and pharmacokinetic/pharmacodynamic profiles support its continued clinical development in immune-inflammatory diseases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Allergy Clin Immunol. 1976 Dec;58(6):676-82 [993482.001]
  • [Cites] Cell Death Dis. 2012 Jun 28;3:e334 [22739986.001]
  • [Cites] Am J Clin Dermatol. 2014 Oct;15(5):379-85 [25027461.001]
  • [Cites] Blood. 2010 Mar 18;115(11):2203-13 [20081091.001]
  • [Cites] Curr Opin Pharmacol. 2015 Aug;23:82-91 [26093105.001]
  • [Cites] Int J Rheum Dis. 2014 May;17(4):359-68 [24460872.001]
  • [Cites] J Invest Dermatol. 2009 Jan;129(1):79-88 [18633443.001]
  • [Cites] Cell Signal. 2011 Apr;23(4):603-8 [20940048.001]
  • [Cites] J Autoimmun. 2011 May;36(3-4):278-87 [21396797.001]
  • [Cites] J Invest Dermatol. 2007 Oct;127(10):2445-52 [17495954.001]
  • [Cites] Ann N Y Acad Sci. 2013 Mar;1280:24-6 [23551098.001]
  • [Cites] J Immunol. 2012 Nov 1;189(9):4612-20 [23024273.001]
  • [Cites] J Invest Dermatol. 2008 May;128(5):1064-7 [18408745.001]
  • [Cites] Trends Immunol. 2007 Feb;28(2):80-7 [17208518.001]
  • [Cites] Open Rheumatol J. 2012;6:245-58 [23028409.001]
  • [Cites] Br J Dermatol. 2014 Jan;170(1):59-65 [24117368.001]
  • [Cites] J Invest Dermatol. 2014 Jan;134(1):268-71 [23812303.001]
  • [Cites] Arch Dermatol Res. 2011 Dec;303(10):691-705 [21863252.001]
  • [Cites] Rheumatology (Oxford). 2015 Feb;54(2):219-30 [25342375.001]
  • [Cites] Rheumatology (Oxford). 2012 Mar;51(3):552-6 [22120603.001]
  • [Cites] J Immunol. 2008 Feb 15;180(4):2538-44 [18250464.001]
  • [Cites] N Engl J Med. 2009 Jul 30;361(5):496-509 [19641206.001]
  • [Cites] Front Immunol. 2012 Aug 23;3:256 [22936933.001]
  • [Cites] Blood. 2007 Oct 15;110(8):2940-7 [17626838.001]
  • [Cites] J Autoimmun. 2015 Dec;65:1-18 [26515757.001]
  • (PMID = 28160012.001).
  • [ISSN] 1432-1041
  • [Journal-full-title] European journal of clinical pharmacology
  • [ISO-abbreviation] Eur. J. Clin. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Placebos; 0 / Pyridines; 0 / Quinolines; 0 / seletalisib; EC 2.7.1.- / Phosphatidylinositol 3-Kinases
  • [Keywords] NOTNLM ; Inflammatory / PI3Kδ / Pharmacodynamic / Pharmacokinetic / Phase I / Seletalisib
  •  go-up   go-down


81. Chalmers JR, Wojnarowska F, Kirtschig G, Mason J, Childs M, Whitham D, Harman K, Chapman A, Walton S, Schmidt E, Godec TR, Nunn AJ, Williams HC: A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial. Health Technol Assess; 2017 Mar;21(10):1-90
Hazardous Substances Data Bank. DOXYCYCLINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial.
  • BACKGROUND: Bullous pemphigoid (BP) is an autoimmune blistering skin disorder with increased morbidity and mortality in the elderly.
  • OBJECTIVES: To evaluate the effectiveness, safety and cost-effectiveness of a strategy of initiating BP treatment with oral doxycycline or oral prednisolone.
  • We hypothesised that starting treatment with doxycycline gives acceptable short-term blister control while conferring long-term safety advantages over starting treatment with oral prednisolone.
  • FUNDING: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in <i>Health Technology Assessment</i>; Vol.
  • [MeSH-minor] Administration, Oral. Aged. Cost-Benefit Analysis. Drug Administration Schedule. Female. Germany. Humans. Male. Quality-Adjusted Life Years. Technology Assessment, Biomedical. United Kingdom

  • Genetic Alliance. consumer health - Bullous Pemphigoid.
  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Pemphigus.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28406394.001).
  • [ISSN] 2046-4924
  • [Journal-full-title] Health technology assessment (Winchester, England)
  • [ISO-abbreviation] Health Technol Assess
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Pragmatic Clinical Trial; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Inflammatory Agents; 9PHQ9Y1OLM / Prednisolone; N12000U13O / Doxycycline
  •  go-up   go-down


82. Watzek N, Berger F, Kolle SN, Kaufmann T, Becker M, van Ravenzwaay B: Assessment of skin sensitization under REACH: A case report on vehicle choice in the LLNA and its crucial role preventing false positive results. Regul Toxicol Pharmacol; 2017 Apr;85:25-32
Hazardous Substances Data Bank. ACETONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of skin sensitization under REACH: A case report on vehicle choice in the LLNA and its crucial role preventing false positive results.
  • In the EU, chemicals with a production or import volume in quantities of one metric ton per year or more have to be tested for skin sensitizing properties under the REACH regulation.
  • This manuscript describes a case study highlighting the importance of understanding the chemistry of the test material during testing for 'skin sensitization' of MCDA (mixture of 2,4- and 2,6-diamino-methylcyclohexane) with particular focus on the vehicle used.
  • Finally, a classification of MCDA as skin sensitizer according to the Globally Harmonized System (GHS) was not justified.

  • Hazardous Substances Data Bank. Propylene glycol .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Inc. All rights reserved.
  • (PMID = 28159477.001).
  • [ISSN] 1096-0295
  • [Journal-full-title] Regulatory toxicology and pharmacology : RTP
  • [ISO-abbreviation] Regul. Toxicol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Allergens; 0 / Cyclohexylamines; 0 / Excipients; 0 / Haptens; 0 / Olive Oil; 1364PS73AF / Acetone; 6DC9Q167V3 / Propylene Glycol
  • [Keywords] NOTNLM ; AOO / Adverse Outcome Pathway / BrdU-ELISA / False positive results / Local Lymph Node Assay / Skin sensitization / Test substance stability in the vehicle
  •  go-up   go-down


83. Fang JY, Huang TH, Hung CF, Huang YL, Aljuffali IA, Liao WC, Lin CF: Derivatization of honokiol by integrated acetylation and methylation for improved cutaneous delivery and anti-inflammatory potency. Eur J Pharm Sci; 2017 Dec 11;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A set of honokiol derivatives was synthesized to evaluate skin permeation and bioactivity.
  • The experimental setup for the assessment of cutaneous absorption was the in vitro Franz diffusion assembly.
  • All derivatives could be completely hydrolyzed to the parent compounds after passing into the skin.
  • The skin deposition of honokiol at an infinite dose (3mM) was 0.33nmol/mg 4'-O-acetylhonokiol (AH), and 2,4'-diacetylhonokiol (DAH) exhibited comparable or less absorption than honokiol.
  • AMH was advantageous for the targeted cutaneous treatment due to the high skin deposition and minimal penetration across the skin (8.40nmol/cm<sup>2</sup> compared to 93.49nmol/cm<sup>2</sup> for honokiol).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017. Published by Elsevier B.V.
  • (PMID = 29241737.001).
  • [ISSN] 1879-0720
  • [Journal-full-title] European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  • [ISO-abbreviation] Eur J Pharm Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Acetylation / Anti-inflammatory activity / Cutaneous absorption / Honokiol / Methylation
  •  go-up   go-down


84. Luo J, Min S: Postoperative pain management in the postanesthesia care unit: an update. J Pain Res; 2017;10:2687-2698

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • More objective assessments of pain being independent of patients' participation may be potentially appropriate in the PACU, including photoplethysmography-derived parameters, analgesia nociception index, skin conductance, and pupillometry, although further studies are needed to confirm their utilities.
  • Being available alternatives to epidural analgesia, perineural techniques and infiltrative techniques including wound infiltration, transversus abdominis plane block, local infiltration analgesia, and intraperitoneal administration have played a more important role for their effectiveness and safety.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pain Physician. 2016 Jul;19(6):341-8 [27454263.001]
  • [Cites] Acta Anaesthesiol Scand. 2015 May;59(5):632-9 [25786811.001]
  • [Cites] Anesthesiology. 2016 Jul;125(1):92-104 [27171827.001]
  • [Cites] Anaesth Intensive Care. 2011 Sep;39(5):804-23 [21970125.001]
  • [Cites] Br J Anaesth. 2005 May;94(5):642-8 [15790675.001]
  • [Cites] Anesth Pain Med. 2015 Dec 05;5(6):e30062 [26705524.001]
  • [Cites] J Pain Res. 2016 Apr 19;9:215-22 [27186073.001]
  • [Cites] J Clin Monit Comput. 2017 Dec;31(6):1273-1281 [27766525.001]
  • [Cites] J Pain Res. 2016 Dec 12;9:1215-1220 [28003771.001]
  • [Cites] P T. 2017 Feb;42(2):125-139 [28163558.001]
  • [Cites] Br J Anaesth. 2015 Dec;115(6):890-5 [26582849.001]
  • [Cites] J Pain Res. 2017 Jun 28;10 :1487-1492 [28721091.001]
  • [Cites] Br J Anaesth. 2006 Dec;97(6):862-5 [17060329.001]
  • [Cites] Minerva Anestesiol. 2014 Jan;80(1):48-57 [23877305.001]
  • [Cites] Curr Ther Res Clin Exp. 2011 Aug;72(4):173-83 [24648587.001]
  • [Cites] Acta Anaesthesiol Scand. 2011 May;55(5):571-6 [21385158.001]
  • [Cites] Br J Anaesth. 2008 Feb;100(2):154-64 [18211990.001]
  • [Cites] Clin J Pain. 1995 Jun;11(2):127-33 [7549168.001]
  • [Cites] PLoS One. 2015 May 21;10(5):e0128450 [25997021.001]
  • [Cites] Pain Res Treat. 2012;2012:612145 [23002426.001]
  • [Cites] Br J Anaesth. 2013 Feb;110(2):191-200 [23220857.001]
  • [Cites] J Pain Res. 2016 Nov 18;9:1073-1079 [27920573.001]
  • [Cites] Eur J Anaesthesiol. 2014 Feb;31(2):91-7 [24225726.001]
  • [Cites] Rev Bras Anestesiol. 2012 Jan-Feb;62(1):28-38 [22248763.001]
  • [Cites] Clin J Pain. 2017 Jun 16;:null [28654558.001]
  • [Cites] Curr Pain Headache Rep. 2017 Feb;21(2):9 [28251524.001]
  • [Cites] Ann Coloproctol. 2014 Aug;30(4):186-91 [25210688.001]
  • [Cites] J Anaesthesiol Clin Pharmacol. 2016 Oct-Dec;32(4):492-496 [28096581.001]
  • [Cites] BMC Surg. 2016 Feb 02;16:5 [26830195.001]
  • [Cites] Anesth Analg. 2015 Jun;120(6):1297-300 [25993266.001]
  • [Cites] Anesth Pain Med. 2015 Dec 05;5(6):e31111 [26705526.001]
  • [Cites] Br J Anaesth. 2016 Sep;117(3):382-6 [27543533.001]
  • [Cites] Anesthesiology. 2004 Jul;101(1):212-27 [15220793.001]
  • [Cites] J Opioid Manag. 2013 Jul-Aug;9(4):281-90 [24353022.001]
  • [Cites] Reg Anesth Pain Med. 2011 Sep-Oct;36(5):417-20 [21897176.001]
  • [Cites] Can J Anaesth. 2017 Mar;64(3):280-289 [28050801.001]
  • [Cites] BMC Anesthesiol. 2017 Jul 5;17 (1):89 [28679359.001]
  • [Cites] Eur J Anaesthesiol. 2015 Jan;32(1):44-8 [24827966.001]
  • [Cites] Br J Anaesth. 2016 Sep;117(3):297-308 [27543524.001]
  • [Cites] Br J Anaesth. 2014 May;112(5):936-7 [24771779.001]
  • [Cites] Br J Surg. 2011 Jan;98(1):29-36 [20979101.001]
  • [Cites] J Pain Res. 2010 May 25;3:67-79 [21197311.001]
  • [Cites] Med Clin North Am. 2016 Jan;100(1):17-30 [26614716.001]
  • [Cites] Anesth Analg. 2013 Aug;117(2):507-13 [23744953.001]
  • [Cites] HSS J. 2016 Jul;12 (2):125-31 [27385940.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2013 Apr;23(2):197-202 [23579518.001]
  • [Cites] Br J Anaesth. 2008 Jul;101(1):77-86 [18434337.001]
  • [Cites] J Res Med Sci. 2013 Aug;18(8):632-6 [24379836.001]
  • [Cites] Anesth Essays Res. 2017 Jan-Mar;11(1):206-210 [28298786.001]
  • [Cites] Br J Anaesth. 2012 May;108(5):838-44 [22369767.001]
  • [Cites] Yale J Biol Med. 2010 Mar;83(1):11-25 [20351978.001]
  • [Cites] Anesth Essays Res. 2016 May-Aug;10(2):324-31 [27212769.001]
  • [Cites] Br J Anaesth. 2014 Apr;112(4):715-21 [24322571.001]
  • [Cites] Lancet. 2011 Jun 25;377(9784):2215-25 [21704871.001]
  • [Cites] J Clin Anesth. 2015 Feb;27(1):23-32 [25468578.001]
  • [Cites] J Clin Anesth. 2017 May;38:133-136 [28372653.001]
  • [Cites] Med Arh. 2012;66(2):111-5 [22486143.001]
  • [Cites] Rev Esp Anestesiol Reanim. 2012 Jan;59(1):12-7 [22429631.001]
  • [Cites] Br J Anaesth. 2016 Sep;117(3):371-4 [27543532.001]
  • [Cites] Pain. 1995 Oct;63(1):65-76 [8577492.001]
  • [Cites] Pain Physician. 2016 Jul;19(6):349-56 [27454264.001]
  • [Cites] Anaesthesia. 2009 Jul;64(7):727-31 [19183409.001]
  • [Cites] Reg Anesth Pain Med. 2015 Jan-Feb;40(1):68-74 [25376971.001]
  • [Cites] Br J Anaesth. 2013 Sep;111(3):453-9 [23592690.001]
  • [Cites] J Anesth. 2014 Dec;28(6):846-53 [24828847.001]
  • [Cites] Anesthesiology. 2012 May;116(5):980-2 [22433239.001]
  • [Cites] J Korean Med Sci. 2016 Sep;31(9):1485-90 [27510395.001]
  • [Cites] Acta Orthop. 2010 Oct;81(5):606-10 [20860447.001]
  • [Cites] J Clin Anesth. 2017 Aug;40:46-50 [28625445.001]
  • [Cites] J Pain Res. 2016 Sep 12;9:631-40 [27672340.001]
  • [Cites] Paediatr Anaesth. 2015 Jan;25(1):73-82 [25410376.001]
  • [Cites] Acta Anaesthesiol Scand. 2014 Sep;58(8):933-41 [24995461.001]
  • [Cites] Anesthesiology. 2009 Feb;110(2):218-30 [19194148.001]
  • [Cites] Anesthesiology. 2014 Sep;121(3):591-608 [25222675.001]
  • [Cites] Drug Healthc Patient Saf. 2013 Jul 03;5:151-9 [23861601.001]
  • [Cites] J Neurosurg Anesthesiol. 2017 Jan 10;:null [28079737.001]
  • [Cites] Acta Anaesthesiol Taiwan. 2014 Sep;52(3):134-42 [25304317.001]
  • [Cites] Br J Anaesth. 2013 Oct;111(4):627-9 [23611914.001]
  • [Cites] Pain Med. 2017 Feb 1;18(2):348-355 [28204722.001]
  • [Cites] Medicine (Baltimore). 2016 Sep;95(36):e4771 [27603376.001]
  • [Cites] Dan Med J. 2012 Apr;59(4):A4401 [22459715.001]
  • [Cites] Anesthesiol Res Pract. 2016;2016:6918327 [26949390.001]
  • [Cites] Anesthesiology. 2010 Jul;113(1):175-82 [20526184.001]
  • [Cites] Best Pract Res Clin Anaesthesiol. 2014 Jun;28(2):191-201 [24993439.001]
  • [Cites] J Clin Monit Comput. 2011 Dec;25(6):371-6 [22037701.001]
  • [Cites] Surg Obes Relat Dis. 2005 Nov-Dec;1(6):530-5; discussion 535-6 [16925285.001]
  • [Cites] PLoS One. 2015 Jun 09;10(6):e0129539 [26056838.001]
  • [Cites] Medicine (Baltimore). 2015 Nov;94(46):e1944 [26579802.001]
  • [Cites] J Altern Complement Med. 2013 Apr;19(4):298-307 [22989077.001]
  • [Cites] Br J Anaesth. 2010 Nov;105(5):675-82 [20736233.001]
  • [Cites] Reg Anesth Pain Med. 2012 Jan-Feb;37(1):72-8 [22157738.001]
  • [Cites] Eur J Anaesthesiol. 2008 Apr;25(4):267-74 [18053314.001]
  • [Cites] Pain Res Manag. 2017;2017:7649458 [28348504.001]
  • [Cites] Anesthesiol Clin. 2016 Jun;34(2):287-301 [27208711.001]
  • [Cites] Yonsei Med J. 2017 May;58(3):650-657 [28332374.001]
  • [Cites] Cochrane Database Syst Rev. 2016 Feb 21;2:CD009121 [26897642.001]
  • [Cites] Lancet. 2006 May 13;367(9522):1618-25 [16698416.001]
  • [Cites] Reg Anesth Pain Med. 2004 Nov-Dec;29(6):576-91 [15635517.001]
  • [Cites] J Clin Anesth. 2012 Aug;24(5):373-7 [22595759.001]
  • [Cites] Anesthesiology. 2013 Feb;118(2):291-307 [23364567.001]
  • [Cites] BMC Musculoskelet Disord. 2015 Mar 18;16:59 [25886746.001]
  • [Cites] Int J Clin Exp Med. 2015 Dec 15;8(12):22460-8 [26885228.001]
  • [Cites] Curr Med Res Opin. 2015 Aug;31(8):1599-607 [26047392.001]
  • [Cites] Acta Anaesthesiol Scand. 2015 Jan;59(1):107-14 [25348807.001]
  • [Cites] Paediatr Anaesth. 2015 Sep;25(9):897-905 [26095747.001]
  • [Cites] Anaesthesia. 2011 Sep;66(9):847-8 [21831090.001]
  • [Cites] J Pain Symptom Manage. 2011 Jun;41(6):1073-93 [21621130.001]
  • [Cites] Br J Anaesth. 2015 Apr;114(4):640-5 [25540069.001]
  • [Cites] J Anaesthesiol Clin Pharmacol. 2014 Jan;30(1):46-52 [24574593.001]
  • [Cites] Surg Endosc. 2016 Jun;30(6):2192-8 [26275549.001]
  • [Cites] Pain Pract. 2017 Mar 30;:null [28371158.001]
  • [Cites] Eur J Anaesthesiol. 2016 Mar;33(3):160-71 [26509324.001]
  • [Cites] Eur J Cardiothorac Surg. 2016 Dec;50(6):1010-1018 [27242357.001]
  • [Cites] J Pain Res. 2017 Apr 12;10 :897-904 [28442931.001]
  • [Cites] J Clin Anesth. 2014 Jun;26(4):294-9 [24882606.001]
  • [Cites] World J Surg. 2012 Dec;36(12):2831-7 [22956016.001]
  • [Cites] Ann Neurosci. 2016 Sep;23 (3):162-170 [27721585.001]
  • [Cites] PLoS One. 2012;7(7):e41758 [22848592.001]
  • [Cites] Anesth Essays Res. 2015 Jan-Apr;9(1):51-6 [25886421.001]
  • [Cites] Ochsner J. 2011 Spring;11(1):17-21 [21603330.001]
  • (PMID = 29180895.001).
  • [ISSN] 1178-7090
  • [Journal-full-title] Journal of pain research
  • [ISO-abbreviation] J Pain Res
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Keywords] NOTNLM ; acute pain / anesthesia recovery period / pain assessment / pain management / postoperative complications
  •  go-up   go-down


85. Armstrong A, Levi E: Real-World Clinical Experience With Apremilast in a Large US Retrospective Cohort Study of Patients With Moderate to Severe Plaque Psoriasis. J Drugs Dermatol; 2017 Dec 01;16(12):1240-1245

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were 7517 adults aged ≥18 years with a psoriasis diagnosis (ICD-9, ICD-10) who received apremilast therapy from October 1, 2015, to January 31, 2016, and were included in effcacy and safety analyses.
  • </p> <p>RESULTS: At apremilast initiation, in systemic-naive and systemic-experienced patients, mean (SD) Physician Global Assessment (PGA) was 2.79 (0.13) and 2.48 (0.15); mean (SD) psoriasis-affected body surface area (BSA) was 17.85% (2.27) and 12.93% (2.59); and mean itch numeric rating scale (NRS; 0=no itch, 10=worst itch possible) score was 4.14 and 3.82, respectively.
  • Of 160 patients with ≥1 assessment of patient-perceived overall treatment effectiveness, 138 (86.2%) strongly/somewhat agreed apremilast was effective in clearing their skin of psoriasis.
  • For safety analyses, body weight was available in the EMR database and decreased in systemic-naive patients (-1.75 kg) and systemic-experienced patients (-1.09 kg).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 29240859.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Moens U, Krumbholz A, Ehlers B, Zell R, Johne R, Calvignac-Spencer S, Lauber C: Biology, evolution, and medical importance of polyomaviruses: An update. Infect Genet Evol; 2017 Oct;54:18-38

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In immunosuppressed individuals, reactivation of polyomavirus BK or JC can cause serious disease of the urogenital tract and brain, respectively, while Merkel cell polyomavirus is most probably associated with the development of a highly aggressive neuroendocrine skin tumour in elderly or patients with pre-existing conditions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier B.V. All rights reserved.
  • (PMID = 28634106.001).
  • [ISSN] 1567-7257
  • [Journal-full-title] Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases
  • [ISO-abbreviation] Infect. Genet. Evol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Disease / Evolution / Interactome / Phylogeny / Prevalence / Replication
  •  go-up   go-down


87. Burnett CL, Fiume MM, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler D, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, Alan Andersen F: Safety Assessment of Plant-Derived Fatty Acid Oils. Int J Toxicol; 2017 Nov/Dec;36(3_suppl):51S-129S

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety Assessment of Plant-Derived Fatty Acid Oils.
  • The Cosmetic Ingredient Review Expert Panel (Panel) assessed the safety of 244 plant-derived fatty acid oils as used in cosmetics.
  • Oils are used in a wide variety of cosmetic products for their skin conditioning, occlusive, emollient, and moisturizing properties.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 29243540.001).
  • [ISSN] 1092-874X
  • [Journal-full-title] International journal of toxicology
  • [ISO-abbreviation] Int. J. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; cosmetics / oils / safety
  •  go-up   go-down


88. Greveling K, Prens EP, Liu L, van Doorn MBA: Non-invasive anaesthetic methods for dermatological laser procedures: a systematic review. J Eur Acad Dermatol Venereol; 2017 Jul;31(7):1096-1110

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of this systematic review was therefore to assess the efficacy and safety of non-invasive anaesthetic methods during dermatological laser procedures.
  • The quality of evidence was rated using Grading of Recommendations Assessment, Development and Evaluation (GRADE).
  • The non-invasive anaesthetic methods (i.e. topical anaesthetic drugs, skin cooling, and pneumatic skin flattening [PSF]), types of lasers, laser settings, application time, and types of pain scales varied widely among the included studies.
  • In general, active non-invasive anaesthetic methods seemed to provide favourable results compared to placebo or no anaesthesia, and topical anaesthetic drugs and PSF seemed to result in a better pain reduction than skin cooling.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 European Academy of Dermatology and Venereology.
  • (PMID = 28107576.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


89. El-Zawawy NA, Fareed MF, Bedaiwy MY: Synthesized zinc peroxide nanoparticles (ZnO&lt;sub&gt;2&lt;/sub&gt;-NPs): a novel antimicrobial, anti-elastase, anti-keratinase, and anti-inflammatory approach toward polymicrobial burn wounds. Int J Nanomedicine; 2017;12:6059-6073

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, the results of in vivo histopathology assessment confirmed the potential role of ZnO<sub>2</sub>-NPs in the improvement of skin wound healing in the experimental animal models.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Microbiol Rev. 2006 Apr;19(2):403-34 [16614255.001]
  • [Cites] Med Mycol. 2004 Jun;42(3):239-46 [15283238.001]
  • [Cites] FEMS Microbiol Rev. 2007 Sep;31(5):570-91 [17645522.001]
  • [Cites] J Bacteriol. 1980 Jun;142(3):836-42 [6769912.001]
  • [Cites] Trends Microbiol. 2011 Nov;19(11):557-63 [21855346.001]
  • [Cites] Mater Sci Eng C Mater Biol Appl. 2014 Nov;44:278-84 [25280707.001]
  • [Cites] J Dent Res. 2010 Nov;89(11):1175-86 [20739694.001]
  • [Cites] Indian J Dermatol. 2011 May;56(3):259-61 [21772583.001]
  • [Cites] J Surg Res. 2012 Nov;178(1):330-8 [22835953.001]
  • [Cites] Toxicol In Vitro. 2014 Dec;28(8):1349-58 [25016134.001]
  • [Cites] Med Mycol. 2005 May;43 Suppl 1:S125-8 [16110804.001]
  • [Cites] Drug Discov Today. 2009 Feb;14(3-4):214-22 [19152839.001]
  • [Cites] J Nanobiotechnology. 2013 Dec 03;11:39 [24298944.001]
  • [Cites] Curr Infect Dis Rep. 2006 Nov;8(6):449-56 [17064638.001]
  • [Cites] Burns. 2016 Mar;42(2):428-33 [26787129.001]
  • [Cites] Burns. 1993 Aug;19(4):345-8 [8357483.001]
  • [Cites] J Pathol. 1971 May;104(1):15-29 [4398139.001]
  • [Cites] Am J Clin Pathol. 1966 Apr;45(4):493-6 [5325707.001]
  • [Cites] J Ind Microbiol Biotechnol. 2009 Feb;36(2):181-8 [19137342.001]
  • [Cites] J Burn Care Res. 2009 May-Jun;30(3):464-70 [19349889.001]
  • [Cites] Int J Pharm. 2014 Mar 25;463(2):119-26 [24361265.001]
  • [Cites] J Invest Dermatol. 2010 Jan;130(1):38-48 [19626034.001]
  • [Cites] FEMS Microbiol Lett. 2009 Oct;299(1):1-8 [19552706.001]
  • [Cites] J Clin Microbiol. 2000 May;38(5):1782-5 [10790099.001]
  • [Cites] Biochem Biophys Res Commun. 2015 Jan 30;457(1):31-6 [25529451.001]
  • [Cites] Sci Technol Adv Mater. 2008 Sep 1;9(3):035004 [27878001.001]
  • [Cites] Acta Biomater. 2013 Nov;9(11):9137-48 [23871941.001]
  • [Cites] Adv Drug Deliv Rev. 2013 Nov;65(13-14):1816-27 [23932923.001]
  • [Cites] J Trace Elem Med Biol. 2015 Apr;30:49-53 [25434301.001]
  • [Cites] Metab Eng. 2016 Nov;38:382-388 [27718358.001]
  • [Cites] Nihon Ishinkin Gakkai Zasshi. 2007;48(1):13-8 [17287718.001]
  • [Cites] Microb Pathog. 2016 Nov;100:213-220 [27671284.001]
  • [Cites] J Egypt Soc Parasitol. 2010 Apr;40(1):71-83 [20503587.001]
  • [Cites] Burns. 1989 Oct;15(5):299-302 [2511853.001]
  • [Cites] Infection. 1992 May-Jun;20(3):132-5 [1644487.001]
  • [Cites] Int J Antimicrob Agents. 2012 Aug;40(2):135-9 [22727529.001]
  • [Cites] J Immunol. 2009 Aug 1;183(3):2089-96 [19597002.001]
  • [Cites] Zhonghua Zheng Xing Shao Shang Wai Ke Za Zhi. 1989 Sep;5(3):199-200, 238-9 [2514028.001]
  • [Cites] J Clin Microbiol. 2002 May;40(5):1811-3 [11980964.001]
  • [Cites] Burns. 2002 Feb;28(1):39-46 [11834328.001]
  • [Cites] J Photochem Photobiol B. 2015 May;146:10-7 [25777265.001]
  • [Cites] Int J Nanomedicine. 2017 Feb 14;12 :1227-1249 [28243086.001]
  • [Cites] Ann Clin Microbiol Antimicrob. 2003 Oct 29;2:8 [14613587.001]
  • [Cites] Int J Antimicrob Agents. 2007 Jun;29(6):630-6 [17306965.001]
  • [Cites] Exp Parasitol. 2009 May;122(1):51-60 [19545520.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14799-804 [20668241.001]
  • [Cites] Indian J Plast Surg. 2010 Sep;43(Suppl):S37-42 [21321655.001]
  • [Cites] J Hosp Infect. 1997 Dec;37(4):317-23 [9457609.001]
  • [Cites] J Pharm Pharmacol. 1968 Mar;20(3):169-73 [4385045.001]
  • [Cites] Nanomedicine. 2014 Aug;10(6):1195-208 [24607937.001]
  • [Cites] Clin Microbiol Infect. 2005 Oct;11 Suppl 5:4-16 [16138814.001]
  • [Cites] Mycopathologia. 1991 Apr;114(1):1-8 [1713301.001]
  • [Cites] Wound Repair Regen. 2014 Jul-Aug;22(4):473-82 [24899251.001]
  • (PMID = 28860766.001).
  • [ISSN] 1178-2013
  • [Journal-full-title] International journal of nanomedicine
  • [ISO-abbreviation] Int J Nanomedicine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Keywords] NOTNLM ; anti-inflammatory / antimicrobial / burn wound infections / co-precipitation method / metal oxides nanoparticles / multidrug resistance
  •  go-up   go-down


90. Nam CH, Park BC, Kim MH, Choi EH, Hong SP: The Efficacy and Safety of 660 nm and 411 to 777 nm Light-Emitting Devices for Treating Wrinkles. Dermatol Surg; 2017 Feb 09;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Efficacy and Safety of 660 nm and 411 to 777 nm Light-Emitting Devices for Treating Wrinkles.
  • BACKGROUND: Low-level light therapy (LLLT) using light-emitting diodes (LEDs) is considered to be helpful for skin regeneration and anti-inflammation.
  • OBJECTIVE: To evaluate the efficacy and safety of 2 types of LLLTs using 660 nm-emitting red LEDs and 411 to 777 nm-emitting white LEDs in the treatment of facial wrinkles.
  • RESULTS: In both groups treated with red and white LEDs, the wrinkle measurement from skin replica improved significantly from baseline at Week 12.
  • In the global assessment of the subjects, the mean improvement score of the red LED group was higher than that of the white LED group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28195844.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Luton A, Hernandez J, Patterson CR, Nielsen-Farrell J, Thompson A, Kaiser JR: Preventing Pressure Injuries in Neonates Undergoing Therapeutic Hypothermia for Hypoxic-Ischemic Encephalopathy: An Interprofessional Quality Improvement Project. Adv Neonatal Care; 2017 Aug;17(4):237-244

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interventions centered on revision of current protocols, with efforts to optimize product selection, hardwire assessment practices, and refine documentation of patient care and outcomes.
  • IMPLICATIONS FOR PRACTICE: Recognizing the unique skin protection needs of special populations within the NICU, such as those undergoing TH, is crucial.
  • IMPLICATIONS FOR RESEARCH: A paucity of literature regarding the unique skin protection needs for babies undergoing TH exists.
  • Work should be done to better describe the influence of TH on skin integrity, with the goal of identifying population-specific protective measures.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28141600.001).
  • [ISSN] 1536-0911
  • [Journal-full-title] Advances in neonatal care : official journal of the National Association of Neonatal Nurses
  • [ISO-abbreviation] Adv Neonatal Care
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Jones IT, Guiha I, Goldman MP, Wu DC: A Randomized Evaluator-Blinded Trial Comparing Subsurface Monopolar Radiofrequency With Microfocused Ultrasound for Lifting and Tightening of the Neck. Dermatol Surg; 2017 Sep 08;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To compare the efficacy and safety of SMRF and MFU-V for the lifting and tightening of neck.
  • MATERIALS AND METHODS: Twenty subjects aged from 18 to 65 with moderate neck skin laxity were randomized to receive either one treatment of SMRF or MFU-V.
  • Subject assessment of firmness, texture, and laxity also significantly improved by Day 90 and persistent to Day 180.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28902019.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Waldmann V, Narayanan K, Combes N, Jost D, Jouven X, Marijon E: Electrical cardiac injuries: current concepts and management. Eur Heart J; 2017 Apr 20;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Electrical injuries can range from minor skin burns to life threatening internal organ damage.
  • A thorough clinical assessment to ascertain the path of current through the body and possible internal injury is essential.
  • Public education and increasing workplace as well as home safety measures are key steps in prevention.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2017. For permissions, please email: journals.permissions@oup.com.
  • (PMID = 28444167.001).
  • [ISSN] 1522-9645
  • [Journal-full-title] European heart journal
  • [ISO-abbreviation] Eur. Heart J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Cardiac arrhythmias / Electric injuries / Lightning / Management / Physiopathology
  •  go-up   go-down


94. Orouji Z, Bajouri A, Ghasemi M, Mohammadi P, Fallah N, Shahbazi A, Rezvani M, Vaezirad F, Khalajasadi Z, Alizadeh A, Taghiabadi E, Dashtbozorgi S, Aghdami R, Hosseini SE, Bahahrvand H, Shafieyan S, Aghdami N: A single-arm open-label clinical trial of autologous epidermal cell transplantation for stable vitiligo: A 30-month follow-up. J Dermatol Sci; 2017 Oct 18;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: In this study, we aimed to investigate the long-term efficacy and safety of this transplantation technique.
  • We obtained a partial thickness normo-pigmented skin specimen from the patients' thigh-buttock junction with an area of one tenth to one third of the recipient site area.
  • The epidermal cell suspension was prepared by processing the autologous skin specimen.
  • An experienced dermatologist and patients respectively defined the repigmentation score and self-assessment score at regular follow-up visits for up to 30 months after treatment.
  • CONCLUSION: The results of our study demonstrated efficacy and safety of autologus epidermal cell transplantation on repigmentation of vitiligo patches.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights reserved.
  • (PMID = 29103774.001).
  • [ISSN] 1873-569X
  • [Journal-full-title] Journal of dermatological science
  • [ISO-abbreviation] J. Dermatol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Cell therapy / Cell transplantation / Clinical trial / Melanocyte / Regenerative medicine / Vitiligo
  •  go-up   go-down


95. Leeies M, Flynn E, Turgeon AF, Paunovic B, Loewen H, Rabbani R, Abou-Setta AM, Ferguson ND, Zarychanski R: High-flow oxygen via nasal cannulae in patients with acute hypoxemic respiratory failure: a systematic review and meta-analysis. Syst Rev; 2017 Oct 16;6(1):202

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: We performed a systematic review and meta-analysis to evaluate the efficacy and safety of high-flow oxygen via nasal cannulae (HFNC) compared to non-invasive ventilation (NIV) and/or standard oxygen in patients with acute, hypoxemic respiratory failure.
  • The strength of evidence was assessed in duplicate using the Grading of Recommendations Assessment, Development and Evaluation framework.
  • Safety outcomes included respiratory arrest, intubation, delirium, and skin breakdown.
  • Delirium and skin breakdown were infrequently reported in included trials.
  • Secondary outcomes including dyspnea, tolerance, and safety were not systematically reported.
  • Prospective trials designed to evaluate the efficacy and safety of HFNC in patients with acute hypoxemic respiratory failure are required.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Intensive Care Med. 2012 Oct;38(10):1573-82 [22926653.001]
  • [Cites] Stat Med. 2002 Jun 15;21(11):1539-58 [12111919.001]
  • [Cites] BMJ. 2008 Apr 26;336(7650):924-6 [18436948.001]
  • [Cites] Br J Anaesth. 2011 Dec;107(6):998-1004 [21908497.001]
  • [Cites] N Engl J Med. 2015 Jun 4;372(23 ):2185-96 [25981908.001]
  • [Cites] Crit Care. 2013 Nov 11;17(6):R269 [24215648.001]
  • [Cites] Chest. 2017 Apr;151(4):764-775 [28089816.001]
  • [Cites] Respir Care. 2012 Oct;57(10 ):1571-7 [22417569.001]
  • [Cites] Respir Care. 2015 Oct;60(10 ):1377-82 [26060321.001]
  • [Cites] Respir Care. 2015 Feb;60(2):170-8 [25294935.001]
  • [Cites] Intensive Care Med. 2015 Apr;41(4):623-32 [25691263.001]
  • [Cites] Int J Epidemiol. 2009 Feb;38(1):287-98 [18824466.001]
  • [Cites] J Crit Care. 2012 Jun;27(3):324.e9-13 [21958974.001]
  • [Cites] BMC Med Res Methodol. 2017 Mar 6;17 (1):39 [28264661.001]
  • [Cites] Respir Care. 2011 Mar;56(3):265-70 [21255498.001]
  • [Cites] Crit Care. 2015 Nov 02;19:380 [26521922.001]
  • [Cites] Respir Care. 2016 Mar;61(3):291-9 [26577199.001]
  • [Cites] Intensive Care Med. 2011 Nov;37(11):1780-6 [21946925.001]
  • [Cites] PLoS Med. 2009 Jul 21;6(7):e1000100 [19621070.001]
  • [Cites] Crit Care Med. 2004 Dec;32(12 ):2516-23 [15599160.001]
  • [Cites] Respir Care. 2017 Jan;62(1):123-132 [27879383.001]
  • [Cites] N Engl J Med. 2000 May 4;342(18):1301-8 [10793162.001]
  • [Cites] Am J Respir Crit Care Med. 2013 Jul 15;188(2):220-30 [23631814.001]
  • [Cites] Cochrane Database Syst Rev. 2013 Dec 09;(12):CD004127 [24323843.001]
  • [Cites] Minerva Anestesiol. 2013 Dec;79(12):1344-55 [23857440.001]
  • [Cites] Crit Care Med. 2017 Apr;45(4):e449-e456 [27611978.001]
  • [Cites] Intensive Care Med. 2015 Sep;41(9):1538-48 [25869405.001]
  • [Cites] Chest. 2000 Mar;117(3):828-33 [10713013.001]
  • [Cites] JAMA. 2015 Jun 16;313(23 ):2331-9 [25980660.001]
  • [Cites] CMAJ. 2017 Feb 21;189(7):E260-E267 [28246239.001]
  • [Cites] Intensive Care Med. 2016 Sep;42(9):1336-49 [26969671.001]
  • [Cites] Respir Care. 2000 May;45(5):480-1 [10813222.001]
  • [Cites] Respir Care. 2010 Apr;55(4):408-13 [20406507.001]
  • [Cites] BMJ. 2011 Oct 18;343:d5928 [22008217.001]
  • [Cites] Cochrane Database Syst Rev. 2004;(3):CD004104 [15266518.001]
  • [Cites] Respir Care. 2011 Aug;56(8):1151-5 [21496369.001]
  • [Cites] Cochrane Database Syst Rev. 2013 May 31;(5):CD005351 [23728654.001]
  • [Cites] Crit Care. 2014 Dec 22;18(6):712 [25529351.001]
  • (PMID = 29037221.001).
  • [ISSN] 2046-4053
  • [Journal-full-title] Systematic reviews
  • [ISO-abbreviation] Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Acute respiratory failure / High flow / Hypoxemic respiratory failure / Nasal cannula / Oxygen therapy / Respiratory failure
  •  go-up   go-down


96. Gibbs S, Kosten I, Veldhuizen R, Spiekstra S, Corsini E, Roggen E, Rustemeyer T, Feilzer AJ, Kleverlaan CJ: Assessment of metal sensitizer potency with the reconstructed human epidermis IL-18 assay. Toxicology; 2018 Jan 15;393:62-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of metal sensitizer potency with the reconstructed human epidermis IL-18 assay.
  • According to the new EU Medical Devices (MDR) legislation coming into effect in 2017, manufactures will have to comply with higher standards of quality and safety for medical devices in order to meet common safety concerns regarding such products.
  • The aim of this study was to further test the applicability domain of the in vitro reconstructed human epidermis (RhE) IL-18 assay developed to identify contact allergens and in doing so: i) determine whether different metal salts, representing leachables from metal alloys used in medical devices, could be correctly labelled and classified; and ii) assess the ability of different salts for the same metal to penetrate the skin stratum corneum.
  • This finding was not related to a lack of stratum corneum skin penetration since EC50 values (decrease in metabolic activity; MTT assay) were obtained after topical RhE exposure to 8 of the 15 metal salts.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 The Author(s). Published by Elsevier B.V. All rights reserved.
  • (PMID = 29079364.001).
  • [ISSN] 1879-3185
  • [Journal-full-title] Toxicology
  • [ISO-abbreviation] Toxicology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Keywords] NOTNLM ; Bioavailability / Cytokine / Immunotoxicity / Medical device / Patch test / in vitro test
  •  go-up   go-down


97. Dornic N, Ficheux AS, Roudot AC: Consumption of cosmetic products by the French population. Third part: Product exposure amount. Food Chem Toxicol; 2017 Aug;106(Pt A):209-222
MedlinePlus Health Information. consumer health - Cosmetics.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of the present study was to generate Product Exposure Amount data, i.e. the amounts of cosmetics applied to the skin among the French population using the raw data collected during the previous enquiry.
  • These data are useful to derive Consumer exposure level data which are paramount for skin sensitization risk assessments.
  • The results showed that some data used by the International Fragrance Association in skin sensitization risk assessments, in particular facial care products and deodorants, could be unsuitable for the protection of French consumers.
  • These data will be useful for the implementation of the Quantitative Risk Assessment for skin sensitization among the French population.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Consumer Product Safety / standards. Databases, Factual. Female. France. Humans. Infant. Male. Skin. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28571772.001).
  • [ISSN] 1873-6351
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cosmetics
  • [Keywords] NOTNLM ; Adults / Babies / Children / Cosmetic products / Product Exposure Amount / Skin sensitization
  •  go-up   go-down


98. Fiume MM, Heldreth B, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, Andersen FA: Safety Assessment of Diethanolamine and Its Salts as Used in Cosmetics. Int J Toxicol; 2017 Sep/Oct;36(5_suppl2):89S-110S

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety Assessment of Diethanolamine and Its Salts as Used in Cosmetics.
  • The Cosmetic Ingredient Review (CIR) Expert Panel assessed the safety of diethanolamine and its salts as used in cosmetics.
  • Diethanolamine functions as a pH adjuster; the 16 salts included in this rereview reportedly function as surfactants, emulsifying agents, viscosity increasing agents, hair or skin conditioning agents, foam boosters, or antistatic agents.
  • Since data were not available for each individual ingredient, and since the salts dissociate freely in water, the Panel extrapolated from previous reports to support safety.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 29025348.001).
  • [ISSN] 1092-874X
  • [Journal-full-title] International journal of toxicology
  • [ISO-abbreviation] Int. J. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; cosmetics / diethanolamine / safety
  •  go-up   go-down


99. Patel NU, Shukla S, Zaki J, Feldman SR: Oxymetazoline hydrochloride cream for facial erythema associated with rosacea. Expert Rev Clin Pharmacol; 2017 Oct;10(10):1049-1054
Hazardous Substances Data Bank. OXYMETAZOLINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Rosacea is a chronic skin condition characterized by transient and persistent erythema of the central face.
  • Our paper seeks to evaluate evidence for topical oxymetazoline HCl with respect to its efficacy and safety for its approved indication of treating the persistent erythema associated with rosacea.
  • Expert commentary: While assessment of available clinical trial data indicates that the medication is as effective as other available treatment for controlling rosacea-associated erythema with minimal risk of adverse effects, studies of long-term duration and direct comparison will be necessary to establish its place in treatment guidelines and clinical practice.
  • [MeSH-minor] Administration, Cutaneous. Adrenergic alpha-Agonists / administration & dosage. Adrenergic alpha-Agonists / adverse effects. Adrenergic alpha-Agonists / pharmacology. Dermatologic Agents / administration & dosage. Dermatologic Agents / adverse effects. Dermatologic Agents / pharmacology. Humans. Skin Cream. Vasoconstriction / drug effects

  • MedlinePlus Health Information. consumer health - Rosacea.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28837365.001).
  • [ISSN] 1751-2441
  • [Journal-full-title] Expert review of clinical pharmacology
  • [ISO-abbreviation] Expert Rev Clin Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adrenergic alpha-Agonists; 0 / Dermatologic Agents; 8VLN5B44ZY / Oxymetazoline
  • [Keywords] NOTNLM ; Erythema / FDA approval oxymetazoline hydrochloride / rhofade / rosacea / topical medication
  •  go-up   go-down


100. McKanna M, Geraci J, Hall K, Hauan B, Howell M, Huey T, Lucius A, Mendez-Eastman S, Purcell K, Raizman R, Shepherd D, Gabriel A: Clinician Panel Recommendations for Use of Negative Pressure Wound Therapy with Instillation. Ostomy Wound Manage; 2016 Apr;62(4):S1-S14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Panelists agreed NPWTi-d is primarily suited to prepare surgical or nonsurgical wounds for delayed primary closure and preparing/protecting periwound skin improves maintenance of a tight seal.
  • Panelists also emphasized the im- portance of wound assessment and documentation and recommend educating the patient, family members, and other members of the patient-care team.
  • Research to compare the safety, ef cacy, and effectiveness of NPWTi-d and other irrigation techniques on patient outcomes and research to validate these recommendations is needed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28657895.001).
  • [ISSN] 1943-2720
  • [Journal-full-title] Ostomy/wound management
  • [ISO-abbreviation] Ostomy Wound Manage
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement